Appendix A: Pediatric Antiretroviral Drug Information

### Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors

- Abacavir (ABC, Ziagen)
- Didanosine (ddI, Videx)
- Emtricitabine (FTC, Emtriva)
- Lamivudine (3TC/Epivir)
- Tenofovir Disoproxil Fumarate (TDF, Viread)
- Zidovudine (ZDV, AZT, Retrovir)
Abacavir (ABC, Ziagen) *(Last updated April 14, 2020; last reviewed April 14, 2020)*

**Formulations**

Pediatric Oral Solution: 20 mg/mL  
Tablet: 300 mg (scored)

**Generic Formulations:**

- 300 mg tablet  
- 20 mg/mL pediatric oral solution

**Fixed-Dose Combination Tablets:**

- [Epzicom and generic] Abacavir 600 mg/lamivudine 300 mg  
- [Triumeq] Abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg  
- [Trizivir and generic] Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg

When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

**Dosing Recommendations**

**Neonate and Infant Dose:**  
Abacavir (ABC) is not approved for use in infants aged <3 months

**Infant and Child (Aged ≥3 Months) Dose**

**Oral Solution:**

- ABC 8 mg/kg twice daily (maximum 300 mg per dose) or ABC 16 mg/kg once daily (maximum 600 mg per dose)
- In infants and young children who are being treated with liquid formulations of ABC, initiation with once-daily ABC is not generally recommended. In older children who can be treated with tablet formulations, therapy can be initiated with once-daily administration. In clinically stable patients who have undetectable viral loads and stable CD4 T lymphocyte cell counts while receiving the liquid formulation of ABC twice daily, the ABC dose can be changed from twice-daily dosing to once-daily dosing with the liquid or tablet formulations (see text below).

**Selected Adverse Events**

- Hypersensitivity reactions (HSRs) can be fatal. HSRs usually occur during the first few weeks of starting therapy. Symptoms may include fever, rash, nausea, vomiting, malaise or fatigue, loss of appetite, and respiratory symptoms (e.g., cough, shortness of breath).

**Special Instructions**

- Test patients for the HLA-B*5701 allele before starting therapy to predict the risk of HSRs. Patients who test positive for the HLA-B*5701 allele should not be given ABC. Patients with no prior HLA-B*5701 testing who are tolerating ABC do not need to be tested.
- Warn patients and caregivers about the risk of serious, potentially fatal HSRs. Occurrence of an HSR requires immediate and permanent discontinuation of ABC. Do not rechallenge.
- ABC can be given without regard to food. The oral solution does not require refrigeration.

- Screen patients for hepatitis B virus (HBV) infection before using Trizivir, Epzicom, and Triumeq (or the generic equivalents of these FDC tablets). These FDC tablets contain lamivudine (3TC), and severe acute
exacerbation of HBV infection can occur when 3TC is discontinued. Therefore, hepatic function and hepatitis B viral load should be monitored for several months after therapy with 3TC is stopped in patients with HBV.

**Metabolism/Elimination**

- ABC is systemically metabolized by alcohol dehydrogenase and glucuronyl transferase.
- The majority of ABC is excreted as metabolites in urine.
- ABC requires a dose adjustment in patients with hepatic insufficiency.
- **Do not use** FDC tablets such as Trizivir, Epzicom, and Triumeq (or the generic equivalents of these FDC tablets) in patients with impaired hepatic function, because the dose of ABC cannot be adjusted.
- **Do not use** Trizivir, Epzicom, and Triumeq (or the generic equivalents of these FDC tablets) in patients with creatinine clearance <50 mL/min and patients on dialysis, because the dose of 3TC cannot be adjusted.

---

**Weight-Band Dosing for Children and Adolescents Weighing ≥14 kg**

<table>
<thead>
<tr>
<th>Weight</th>
<th>Scored 300-mg Tablet</th>
<th>Twice-Daily Dose, AM</th>
<th>Twice-Daily Dose, PM</th>
<th>Once-Daily Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 kg to &lt;20 kg</td>
<td>½ tablet (150 mg)</td>
<td>½ tablet (150 mg)</td>
<td>1 tablet (300 mg)</td>
<td></td>
</tr>
<tr>
<td>≥20 kg to &lt;25 kg</td>
<td>½ tablet (150 mg)</td>
<td>1 tablet (300 mg)</td>
<td>1½ tablets (450 mg)</td>
<td></td>
</tr>
<tr>
<td>≥25 kg</td>
<td>1 tablet (300 mg)</td>
<td>1 tablet (300 mg)</td>
<td>2 tablets (600 mg)</td>
<td></td>
</tr>
</tbody>
</table>

**Child and Adolescent (Weighing ≥25 kg) and Adult Dose:**

- ABC 300 mg twice daily or ABC 600 mg once daily

**Epzicom Abacavir/Lamivudine**

- **Child and Adolescent (Weighing ≥25 kg) and Adult Dose:**
  - One tablet once daily

**Triumeq Abacavir/Dolutegravir/Lamivudine**

- **Child and Adolescent (Weighing ≥25 kg) and Adult Dose:**
  - One tablet once daily
  - This FDC tablet can be used in patients who are antiretroviral (ARV)-naive or ARV-experienced (but integrase strand transfer inhibitor-naive) and who are not being treated with uridine diphosphosphate glucuronosyltransferase 1A1 or cytochrome P450 3A inducers.
  - The Food and Drug Administration-approved dose for pediatric patients is one tablet once daily for patients weighing ≥40 kg (see the [Dolutegravir](https://aidsinfo.nih.gov/guidelines) section for more information).

**Trizivir Abacavir/Lamivudine/Zidovudine**

- **Child and Adolescent (Weighing ≥30 kg) and Adult Dose:**
  - One tablet twice daily
### Emtricitabine (FTC, Emtriva) (Last updated April 14, 2020; last reviewed April 14, 2020)

**Formulations**

**Pediatric Oral Solution:** 10 mg/mL  
**Capsule:** 200 mg  
**Fixed-Dose Combination Tablets:**
- [Atripla and generic] Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg  
- [Biktarvy] Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg  
- [Complera] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg  
- [Descovy] Emtricitabine 200 mg/tenofovir alafenamide 25 mg  
- [Genvoya] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg  
- [Odefsey] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg  
- [Stribild] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg  
- [Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg  
- [Truvada] Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg  
- [Truvada low-strength tablets]
  - Emtricitabine 100 mg/tenofovir disoproxil fumarate 150 mg  
  - Emtricitabine 133 mg/tenofovir disoproxil fumarate 200 mg  
  - Emtricitabine 167 mg/tenofovir disoproxil fumarate 250 mg

When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

### Dosing Recommendations

#### Neonatal and Infant (Aged 0 to <3 Months) Dose

**Oral Solution:**
- Emtricitabine (FTC) 3 mg/kg once daily

#### Child (Aged ≥3 Months) and Adolescent Dose

**Oral Solution:**
- FTC 6 mg/kg once daily (maximum 240 mg per dose). The maximum dose of oral solution is higher than the capsule dose because a pediatric pharmacokinetic analysis reported that the plasma exposure for FTC was 20% lower in patients who received the oral solution than in patients who received the capsule formulation.

**Capsules (For Patients Weighing >33 kg):**
- FTC 200 mg once daily

#### Adult Dose

**Oral Solution for Patients Who Are Unable to Swallow Capsules:**
- FTC 240 mg (24 mL) once daily

### Selected Adverse Events

- Hyperpigmentation/skin discoloration on palms and/or soles

### Special Instructions

- Although FTC can be administered without regard to food, there are food requirements for some FDC tablet formulations that contain FTC.
- FTC oral solution can be kept at room temperature, up to 77°F (25°C), if used within 3 months; refrigerate oral solution for long-term storage.
- Screen patients for hepatitis B virus (HBV) infection before using FTC. Severe acute exacerbation of HBV infection can occur when FTC is discontinued; therefore, hepatic function and hepatitis B viral load should be monitored for several months after patients with HBV infection stop taking FTC.
Metabolism/Elimination

- No cytochrome P450 interactions
- Eighty-six percent of FTC is excreted in urine. FTC may compete with other compounds that undergo renal elimination.

Emtricitabine Dosing in Patients with Renal Impairment:

- Decrease the dose of FTC in patients with impaired renal function. Consult the manufacturer’s prescribing information for recommended dose adjustments.
- Do not use the FDC tablet Atripla in patients with creatinine clearance (CrCl) <50 mL/min or in patients who require dialysis.
- Do not use the FDC tablets Truvada or Biktarvy in patients with CrCl <30 mL/min. Do not use Truvada in patients who require dialysis.
- Use Complera with caution in patients with severe renal impairment or end-stage renal disease. Monitor frequently for adverse events, because rilpivirine concentrations may increase in patients with severe renal impairment or end-stage renal disease.
- Stribild should not be initiated in patients with estimated CrCl <70 mL/min and should be discontinued in patients with estimated CrCl <50 mL/min.
- TAF-containing formulations are not recommended for use in patients with estimated CrCl <30 mL/min.

Capsules:

- FTC 200 mg once daily

[Atripla and Generic] Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Child and Adolescent (Weighing ≥40 kg) and Adult Dose:

- One tablet once daily
- Take on an empty stomach.

[Biktarvy] Bictegravir/Emtricitabine/Tenofovir Alafenamide (TAF)

Child (Weighing <25 kg) Dose:

- There are currently no data available on the appropriate dose of Biktarvy in children aged <6 years and weighing <25 kg. Studies are currently being conducted to identify the appropriate dose for this age and weight group.

Child and Adolescent (Weighing ≥25 kg) and Adult Dose:

- One tablet once daily with or without food in antiretroviral therapy (ART)-naive patients. This dose of Biktarvy can also be used to replace the current antiretroviral (ARV) regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 3 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Biktarvy.
- See the Bictegravir section for additional information.

[Complera] Emtricitabine/Rilpivirine/TDF

Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose:

- One tablet once daily in ART-naive patients who have baseline plasma HIV RNA ≤100,000 copies/mL. This dose of Complera can also be used to replace a stable ARV regimen in patients who are currently on their first or second regimen and who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Complera.
- Administer with a meal of at least 500 calories.

[Descovy] Emtricitabine/TAF

Child and Adolescent (Weighing ≥25 kg) and Adult Dose:
Body Weight 25 kg to <35 kg:
- One tablet once daily in combination with other ARV agents, except for protease inhibitors (PIs) that require a cytochrome P450 3A inhibitor (i.e., Descovy can be used in combination with an integrase strand transfer inhibitor [INSTI] or a non-nucleoside reverse transcriptase inhibitor [NNRTI], but not a boosted PI).

Body Weight ≥35 kg:
- One tablet once daily in combination with an INSTI, NNRTI, or boosted PI.

**[Genvoya] Elvitegravir/Cobicistat/Emtricitabine/TAF**
*Child and Adolescent (Weighing ≥25 kg) and Adult Dose:*
- One tablet once daily with food in ART-naive patients. This dose of Genvoya can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Genvoya.

**[Odefsey] Emtricitabine/Rilpivirine/TAF**
*Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose:*
- One tablet once daily in ART-naive patients with HIV RNA ≤100,000 copies per mL. This dose of Odefsey can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Odefsey.
- Administer with a meal of at least 500 calories.

**[Stribild] Elvitegravir/Cobicistat/Emtricitabine/TDF**
*Child and Adolescent (Weighing ≥35 kg with a Sexual Maturity Rating of 4 or 5) and Adult Dose:*
- One tablet once daily with food in ART-naive patients. This dose of Stribild can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) for at
least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Stribuilt.

**[Symtuza] Darunavir/Cobicistat/Emtricitabine/TAF**

*Child and Adolescent (Weighing ≥ 40 kg) and Adult Dose:*

- One tablet once daily with food in ART-naive patients or in patients who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no known mutations associated with resistance to darunavir or tenofovir.

**[Truvada] Emtricitabine/TDF (FTC/TDF)**

*Child, Adolescent, and Adult Dose:*

**Truvada Dosing Table**

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>FTC/TDF Tablet Once Daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 kg to &lt;22 kg</td>
<td>One FTC 100 mg/TDF 150 mg tablet</td>
</tr>
<tr>
<td>22 kg to &lt;28 kg</td>
<td>One FTC 133 mg/TDF 200 mg tablet</td>
</tr>
<tr>
<td>28 kg to &lt;35 kg</td>
<td>One FTC 167 mg/TDF 250 mg tablet</td>
</tr>
<tr>
<td>≥35 kg and Adults</td>
<td>One FTC 200 mg/TDF 300 mg tablet</td>
</tr>
</tbody>
</table>
Lamivudine (3TC, Epivir) (Last updated April 14, 2020; last reviewed April 14, 2020)

Formulations

Pediatric Oral Solution:
- [Epivir] 10 mg/mL
- [Epivir HBV]* 5 mg/mL

Tablets:
- [Epivir] 150 mg (scored) and 300 mg
- [Epivir HBV] 100 mg

Generic Formulations:
- 100 mg, 150 mg, and 300 mg tablets
- Fixed-dose combination (FDC) tablet containing lamivudine 150 mg/zidovudine 300 mg

Fixed-Dose Combination Tablets:
- [Cimduo] Lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Combivir and generic] Lamivudine 150 mg/zidovudine 300 mg
- [Delstrigo] Doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Dovato] Dolutegravir 50 mg/lamivudine 300 mg
- [Epzicomp] Abacavir 600 mg/lamivudine 300 mg
- [Symfi] Efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Symfi Lo] Efavirenz 400 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Temixys] Lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Triumeq] Abacavir 300 mg/dolutegravir 50 mg/lamivudine 300 mg
- [Trizivir] Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg

When using FDC tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

Dosing Recommendations

Note: See Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection and Table 12 for information about using lamivudine (3TC) for the prevention of perinatal HIV transmission.

Neonate (≥32 Weeks Gestation at Birth) and Infant (Birth to <4 Weeks) Dose

Oral Solution:
- 3TC 2 mg/kg twice daily

Infant and Child Dose:
- Once-daily dosing of the 3TC oral solution is not recommended when initiating 3TC oral solution in infants and young children. Patients can be transitioned to once-daily treatment with the oral solution when they

Selected Adverse Events

- Severe exacerbation of hepatitis can occur in patients with hepatitis B virus (HBV)/HIV co-infection who discontinue 3TC.

Special Instructions

- 3TC can be given without regard to food.
- Store 3TC oral solution at room temperature.
- Screen patients for HBV infection before using 3TC or FDC tablets that contain 3TC. Hepatic function and hepatitis B viral load should be monitored for several months after patients with HBV infection stop taking 3TC. Patients with HBV/HIV co-infection who receive Dovato will require additional treatment for chronic HBV infection.
have been stable on twice-daily treatment for 36 weeks and are aged ≥3 years. Please see the note below and refer to the text for more detail.

_Aged ≥4 Weeks to <3 Months:_
- 3TC 4 mg/kg twice daily of the oral solution

_Aged ≥3 Months to <3 Years:_
- 3TC 5 mg/kg twice daily of the oral solution (maximum 150 mg per dose)

_Aged ≥3 Years:_
- 3TC 5 mg/kg twice daily of the oral solution (maximum 150 mg per dose); or
- 3TC 10 mg/kg once daily of the oral solution (maximum 300 mg per dose)

### Weight-Band Dosing for the 10 mg/mL Lamivudine Oral Solution in Children Weighing ≥3 kg

<table>
<thead>
<tr>
<th>Weight</th>
<th>Twice-Daily Dose, AM</th>
<th>Twice-Daily Dose, PM</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 kg to 5.9 kg</td>
<td>3 ml</td>
<td>3 ml</td>
</tr>
<tr>
<td>6 kg to 9.9 kg</td>
<td>4 ml</td>
<td>4 ml</td>
</tr>
<tr>
<td>10 kg to 13.9 kg</td>
<td>6 ml</td>
<td>6 ml</td>
</tr>
</tbody>
</table>

_Weighing ≥14 kg and Able to Swallow Tablets:_
- Weight-band dosing (see table below; dose is approximately 3TC 5 mg/kg per day twice daily or 3TC 10 mg/kg once daily)
- The scored tablet is the preferred formulation for pediatric patients weighing ≥14 kg who can swallow a tablet.

### Weight-Band Dosing for the Scored, 150-mg Lamivudine Tablet in Children Weighing ≥14 kg

<table>
<thead>
<tr>
<th>Weight</th>
<th>Twice-Daily Dose, AM</th>
<th>Twice-Daily Dose, PM</th>
<th>Once-Daily Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 kg to &lt;20 kg</td>
<td>½ tablet (75 mg)</td>
<td>½ tablet (75 mg)</td>
<td>1 tablet (150 mg)</td>
</tr>
<tr>
<td>≥20 kg to &lt;25 kg</td>
<td>½ tablet (75 mg)</td>
<td>1 tablet (150 mg)</td>
<td>1½ tablets (225 mg)</td>
</tr>
<tr>
<td>≥25 kg</td>
<td>1 tablet (150 mg)</td>
<td>1 tablet (150 mg)</td>
<td>2 tablets (300 mg)</td>
</tr>
</tbody>
</table>

_NOTE:_ The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) supports switching from twice-daily dosing to once-daily dosing of 3TC (using the oral solution or tablets) in children aged ≥3 years who have been clinically stable for 36 weeks

### Metabolism/Elimination
- Dose adjustment is required for patients with renal insufficiency.
- FDC tablets should not be used in patients who are on dialysis, patients who have creatinine clearance <50 mL/min, or patients who have impaired hepatic function.
with undetectable viral loads and stable CD4 T lymphocyte counts. Clinicians should choose a once-daily regimen using the once-daily dose of 3TC indicated above (approximately 3TC 10 mg/kg, with a maximum of 3TC 300 mg once daily).

**Child and Adolescent (Weighing ≥25 kg) and Adult Dose:**
- 3TC 150 mg twice daily; or
- 3TC 300 mg once daily

**[Cimduo] Lamivudine/Tenofovir Disoproxil Fumarate (TDF)**
*Child and Adolescent (Weighing >35 kg) and Adult Dose:*
- One tablet once daily

**[Combi vir and Generic] Lamivudine/Zidovudine**
*Child and Adolescent (Weighing ≥30 kg) and Adult Dose:*
- One tablet twice daily

**[Delstrigo] Doravirine/Emtricitabine/TDF**
*Adult Dose:*
- One tablet once daily
- The use of Delstrigo has not been studied in children or adolescents (see the Doravirine section for more information).

**[Dovato] Dolutegravir/Lamivudine**
*Adult Dose:*
- One tablet once daily with or without food as a complete antiretroviral (ARV) regimen in antiretroviral therapy (ART)-naive adults with no known mutations associated with resistance to the individual components of Dovato.
- Dovato is not approved by the Food and Drug Administration (FDA) or recommended by the Panel for use in children or adolescents as a complete ARV regimen. However, it could be used as part of a three-drug regimen in patients who meet the minimum body weight requirements for each component drug.

**[Epzicom] Abacavir/Lamivudine**
*Child and Adolescent (Weighing ≥25 kg) and Adult Dose:*
- One tablet once daily

**[Symfi] Efavirenz 600 mg/Lamivudine/TDF**
*Child and Adolescent (Weighing ≥40 kg) and Adult Dose:*
- One tablet once daily on an empty stomach
**[Symfi Lo] Efavirenz 400 mg/Lamivudine/TDF**  
*Child and Adolescent (Weighing ≥35 kg) and Adult Dose:*

- One tablet once daily on an empty stomach
- Symfi Lo has not been studied in children (sexual maturity ratings [SMRs] 1–3), and major interindividual variability in efavirenz (EFV) plasma concentrations has been found in pediatric patients in a multi-ethnic setting. The 400 mg dose of EFV may be too low in children or adolescents with SMRs 1 to 3 who weigh ≥40 kg. The use of therapeutic drug monitoring is suggested by some Panel members when Symfi Lo is used in pediatric patients who weigh ≥40 kg. See the **Efavirenz** section for more information.

**[Temixys] Lamivudine/TDF**  
*Child and Adolescent (Weighing ≥35 kg) and Adult Dose:*

- One tablet once daily

**[Triumeq] Abacavir/Dolutegravir/Lamivudine**  
*Child and Adolescent (Weighing ≥25 kg) and Adult Dose:*

- One tablet once daily
- This FDC tablet can be used in patients who are ART-naive or ART-experienced (but integrase strand transfer inhibitor-naive) and who are not being treated with uridine diphosphate glucuronosyltransferase 1A1 or cytochrome P450 3A inducers.
- The FDA-approved dose for pediatric patients is one tablet once daily for patients weighing ≥40 kg (see the **Dolutegravir** section for more information).

**[Trizivir and Generic] Abacavir/Lamivudine/ Zidovudine**  
*Child and Adolescent (Weighing ≥30 kg) and Adult Dose:*

- One tablet twice daily
Tenofovir Alafenamide (TAF, Vemlidy) (Last updated April 14, 2020; last reviewed April 14, 2020)

Formulations
Tablets: 25 mg

Fixed-Dose Combination Tablets:
- [Biktarvy] Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg
- [Descovy] Emtricitabine 200 mg/tenofovir alafenamide 25 mg
- [Genvoya] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg
- [Odefsey] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg
- [Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg

When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

Dosing Recommendations

[Biktarvy] Bictegravir/Emtricitabine/Tenofovir Alafenamide (TAF)
Child (Weighing <25 kg) Dose:
- There are no data on the appropriate dose of Biktarvy in children weighing <25 kg. Studies are currently being conducted to identify the appropriate dose for this age and weight group.

Child and Adolescent (Weighing ≥25 kg) and Adult Dose:
- One tablet once daily with or without food in antiretroviral therapy (ART)-naive patients. This dose of Biktarvy can also be used to replace the current antiretroviral (ARV) regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 3 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Biktarvy.
- See the Bictegravir section for additional information.

[Descovy] Emtricitabine/TAF
Child and Adolescent (Weighing ≥25 kg) and Adult Dose
Body Weight 25 kg to <35 kg:
- One tablet once daily in combination with other ARV agents, except for protease inhibitors (PIs) that require a cytochrome P450 3A inhibitor (i.e., Descovy can be used in combination with an integrase strand

Selected Adverse Events
- Asthenia, headache, diarrhea, nausea
- Increased serum lipids

Special Instructions
- Measure serum creatinine before starting a TAF-containing regimen.
- Screen patients for hepatitis B virus (HBV) infection before initiating TAF. Severe acute exacerbation of HBV infection can occur when TAF is discontinued; therefore, hepatic function should be monitored for several months after patients with HBV infection stop taking TAF.
- The Food and Drug Administration (FDA) does not recommend using Genvoya with other ARV drugs, but this FDC tablet has safely been used with darunavir (DRV). Descovy can be safely used with DRV or atazanavir in patients weighing ≥35 kg.
- Do not use Genvoya with elvitegravir, COBI, tenofovir disoproxil fumarate, emtricitabine, lamivudine, or PIs that are coformulated with COBI.
- When using Odefsey, patients must be able to take it with a meal of at least 500 calories on a regular schedule (a protein drink alone does not constitute a meal) because it contains rilpivirine.

Metabolism/Elimination
TAF Dosing in Patients with Hepatic Impairment:
- TAF-containing formulations do not require dose adjustment in patients with mild or
transfer inhibitor [INSTI] or a non-nucleoside reverse transcriptase inhibitor [NNRTI], but not a boosted PI.

**Body Weight ≥35 kg:**
- One tablet once daily in combination with an INSTI, NNRTI, or boosted PI.

**[Genvoya] Elvitegravir/Cobicistat/Emtricitabine/TAF**

*Child and Adolescent (Weighing ≥25 kg) and Adult Dose:*
- One tablet once daily with food in ART-naive patients. This dose of Genvoya can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Genvoya.

**[Odefsey] Emtricitabine/Rilpivirine/TAF**

*Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose:*
- One tablet once daily with a meal in ART-naive patients with HIV RNA ≤100,000 copies/mL. This dose of Odefsey can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Odefsey.

**[Symtuza] Darunavir/Cobicistat/Emtricitabine/TAF**

*Child and Adolescent (Weighing ≥40 kg) and Adult Dose:*
- One tablet once daily with food in ART-naive patients. This dose of Symtuza can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Symtuza.

TAF Dosing in Patients with Renal Impairment:
- TAF is renally excreted.
  - No dose adjustment of the TAF 25-mg tablet (Vemlidy)* is required in patients with estimated creatinine clearance (CrCl) ≥15 mL/min, or in patients with estimated CrCl <15 mL/min (i.e., end stage renal disease) who are receiving chronic hemodialysis. See the Vemlidy product label for information on the use of the TAF 25 mg tablet in patients with estimated CrCl ≤15 mL/min.3
  - TAF-containing coformulations are not recommended for use in patients with estimated CrCl <30 mL/min.

---

* TAF 25-mg tablets (Vemlidy) are approved by the FDA for treatment of HBV. In certain circumstances, TAF 25 mg tablets (Vemlidy) might be used as one component of a combination ARV regimen, with dosing recommendations similar to those for Descovy.
Dosing Recommendations

Neonate and Infant Dose:
- Tenofovir disoproxil fumarate (TDF) has not been approved by the Food and Drug Administration or recommended for use in neonates and infants aged <2 years.

Child (Aged ≥2 Years to <12 Years) Dose:
- TDF 8 mg/kg per dose once daily

Selected Adverse Events
- Asthenia, headache, diarrhea, nausea, vomiting, flatulence
- Glomerular and proximal renal tubular dysfunction
- Decreased bone mineral density

Special Instructions
- TDF oral powder formulation is available for patients who are unable to swallow tablets.
- TDF oral powder should be measured only with the supplied dosing scoop: one level scoop = 1 g powder = TDF 40 mg.
- Mix TDF oral powder with 2 to 4 oz. of soft food that does not require chewing (e.g., applesauce, yogurt). Administer immediately after mixing to avoid the bitter taste.
- Do not try to mix the TDF oral powder with

Formulations

Oral Powder: 40 mg per 1 g of oral powder (one level scoop, measured with supplied dosing scoop = 1 g oral powder)

Tablets: 150 mg, 200 mg, 250 mg, and 300 mg

Fixed-Dose Combination Tablets
- [Atripla and generic] Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg
- [Cimduo] Lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Complera] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg
- [Delstrigo] Doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Stribild] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg
- [Symfii] Efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Symfi Lo] Efavirenz 400 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Temixys] Lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg
- [Truvada tablet] Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg
- [Truvada low-strength tablet]
  - Emtricitabine 100 mg/tenofovir disoproxil fumarate 150 mg
  - Emtricitabine 133 mg/tenofovir disoproxil fumarate 200 mg
  - Emtricitabine 167 mg/tenofovir disoproxil fumarate 250 mg

When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.
Child and Adolescent (Weighing ≥35 kg) and Adult Dose:

- TDF 300 mg once daily

**[Atripla and Generic] Efavirenz/Emtricitabine/TDF**

**Child and Adolescent (Weighing ≥40 kg) and Adult Dose:**

- One tablet once daily
- Take on an empty stomach.

**[Cimduo] Lamivudine/TDF**

**Child and Adolescent (Weighing ≥35 kg) and Adult Dose:**

- One tablet once daily

**[Complera] Emtricitabine/Rilpivirine/TDF**

**Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose:**

- One tablet once daily in antiretroviral therapy (ART)-naive adults with baseline HIV RNA ≤100,000 copies/mL. This dose of Complera can also be used in virologically suppressed (HIV RNA <50 copies/mL) adults who are currently on their first or second regimen and who have no history of virologic failure or resistance to rilpivirine and other antiretroviral (ARV) drugs.

- Although TDF can be administered without regard to food, food requirements vary depending on the other ARV drugs contained in an FDC tablet. Food requirements are listed with dosing recommendations and in Table 2 of the Drug Appendix.

- Measure serum creatinine and perform a urine dipstick test for protein and glucose before starting a TDF-containing regimen. Serum creatinine should be monitored and urine should be tested for protein and glucose at intervals during continued therapy (see Table 15i). Measure serum phosphate if there is clinical suspicion of hypophosphatemia.

- Screen patients for hepatitis B virus (HBV) infection before using TDF. Severe acute exacerbation of HBV infection can occur when TDF is discontinued; therefore, hepatic function should be monitored for several months after patients with HBV infection stop taking TDF.

- Tenofovir alafenamide (TAF) is associated with less bone and renal toxicity than TDF, but it has equal antiviral efficacy. **Do not use TAF and TDF together.** Consider switching from TDF to TAF in appropriate clinical settings.

**Metabolism/Elimination**

**TDF Dosing in Patients with Renal Insufficiency:**

- TDF is renally excreted.
- The dose of TDF should be decreased in patients with impaired renal function (creatinine clearance [CrCl] <50 mL/min). Consult the manufacturer’s prescribing information for directions on how to adjust the dose in accordance with CrCl.
- The FDCs Atripla, Complera, and Symfi Lo should not be used in patients with CrCl <50 mL/min or in patients who require dialysis.
- The FDC Truvada should not be used in patients with CrCl <30 mL/min or in patients who require dialysis.
- The FDC Stribild should not be initiated in patients with estimated CrCl <70 mL/min and should be discontinued in patients with estimated CrCl <50 mL/min.
- Stribild should not be used in patients with severe hepatic impairment.

**TDF Oral Powder Dosing Table**

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>TDF Oral Powder Once-Daily Scoops of Powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 kg to &lt;12 kg</td>
<td>2 scoops (80 mg)</td>
</tr>
<tr>
<td>12 kg to &lt;14 kg</td>
<td>2.5 scoops (100 mg)</td>
</tr>
<tr>
<td>14 kg to &lt;17 kg</td>
<td>3 scoops (120 mg)</td>
</tr>
<tr>
<td>17 kg to &lt;19 kg</td>
<td>3.5 scoops (140 mg)</td>
</tr>
<tr>
<td>19 kg to &lt;22 kg</td>
<td>4 scoops (160 mg)</td>
</tr>
<tr>
<td>22 kg to &lt;24 kg</td>
<td>4.5 scoops (180 mg)</td>
</tr>
<tr>
<td>24 kg to &lt;27 kg</td>
<td>5 scoops (200 mg)</td>
</tr>
<tr>
<td>27 kg to &lt;29 kg</td>
<td>5.5 scoops (220 mg)</td>
</tr>
<tr>
<td>29 kg to &lt;32 kg</td>
<td>6 scoops (240 mg)</td>
</tr>
<tr>
<td>32 kg to &lt;34 kg</td>
<td>6.5 scoops (260 mg)</td>
</tr>
<tr>
<td>34 kg to &lt;35 kg</td>
<td>7 scoops (280 mg)</td>
</tr>
<tr>
<td>≥35 kg</td>
<td>7.5 scoops (300 mg)</td>
</tr>
</tbody>
</table>

**TDF Tablet Dosing Table for Patients Aged ≥2 Years and Weighing ≥17 kg**

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>TDF Tablet Once Daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 kg to &lt;22 kg</td>
<td>150 mg</td>
</tr>
<tr>
<td>22 kg to &lt;28 kg</td>
<td>200 mg</td>
</tr>
<tr>
<td>28 kg to &lt;35 kg</td>
<td>250 mg</td>
</tr>
<tr>
<td>≥35 kg</td>
<td>300 mg</td>
</tr>
</tbody>
</table>
Administer with a meal of ≥500 calories.

**[Delstrigo] Doravirine/Emtricitabine/TDF**

**Adult Dose:**
- One tablet once daily in ART-naive adults. This dose of Delstrigo can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known mutations associated with resistance to the individual components of Delstrigo.
- Not studied in children or adolescents (see the Doravirine section for more information)

**[Stribild] Elvitegravir/Cobicistat/Emtricitabine/TDF**

**Adolescent (Weighing >35 kg with a Sexual Maturity Rating [SMR] of 4 or 5) and Adult Dose:**
- One tablet once daily in ART-naive adults. This dose of Stribild can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Stribild.
- Administer with food.

**[Symfi] Efavirenz 600 mg/Lamivudine/TDF**

**Child and Adolescent (Weighing ≥40 kg) and Adult Dose:**
- One tablet once daily
- Take on an empty stomach.

**[Symfi Lo] Efavirenz 400 mg/Lamivudine/TDF**

**Child and Adolescent (Weighing ≥35 kg) and Adult Dose:**
- One tablet once daily
- Take on an empty stomach.
- Symfi Lo has not been studied in children (SMR 1 to 3), and major inter-individual variability in efavirenz (EFV) plasma concentrations has been found in pediatric patients in a multi-ethnic setting. The 400-mg dose of EFV may be too low in children or adolescents with SMRs of 1 to 3 who weigh ≥40 kg. Therapeutic drug monitoring is suggested by some Panel members when Symfi Lo is used in pediatric patients weighing ≥40 kg. See the Efavirenz section for more information.
information.

[Temixys] Lamivudine/TDF
Child and Adolescent (Weighing ≥35 kg) and Adult Dose:
• One tablet once daily

[Truvada] Emtricitabine/TDF (FTC/TDF)
Child, Adolescent, and Adult Dose:
Truvada Dosing Table

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>FTC/TDF Tablet Once Daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>17 kg to &lt;22 kg</td>
<td>One FTC 100 mg/TDF 150 mg tablet</td>
</tr>
<tr>
<td>22 kg to &lt;28 kg</td>
<td>One FTC 200 mg/TDF 133 mg tablet</td>
</tr>
<tr>
<td>28 kg to &lt;35 kg</td>
<td>One FTC 167 mg/TDF 250 mg tablet</td>
</tr>
<tr>
<td>≥35 kg and adults</td>
<td>One FTC 200 mg/TDF 300 mg tablet</td>
</tr>
</tbody>
</table>

* See text for a discussion of the concerns about decreased bone mineral density in patients who are receiving TDF, especially in prepubertal patients and those in early puberty (SMR 1 or 2).
Zidovudine (ZDV, Retrovir) (Last updated April 14, 2020; last reviewed April 14, 2020)

Formulations
Capsule: 100 mg
Syrup: 10 mg/mL
Concentrate for Injection or Intravenous Infusion: 10 mg/mL (Retrovir)

Generic Formulations:
- 100 mg capsule
- 10 mg/mL syrup
- 300 mg tablet

Fixed-Dose Combination Tablets:
- [Combivir and generic] Lamivudine 150 mg/zidovudine 300 mg (scored)
- [Trizivir and generic] Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg

When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

Dosing Recommendations

Note: Zidovudine (ZDV) is frequently used in neonates to prevent perinatal transmission of HIV. See Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection and Table 12 for information about using ZDV to prevent perinatal transmission.

Recommended Neonatal Dose for Treatment of HIV by Gestational Age at Birtha

<table>
<thead>
<tr>
<th>Gestational Age at Birth</th>
<th>Oral ZDV Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥35 weeks</td>
<td>Birth to Age 4 Weeks:</td>
</tr>
<tr>
<td></td>
<td>- ZDV 4 mg/kg twice daily; or</td>
</tr>
<tr>
<td></td>
<td>- Alternative simplified weight-band dosing</td>
</tr>
<tr>
<td></td>
<td>Simplified Weight-Band Dosing for Infants with a Gestational Age ≥35 Weeks at Birth:</td>
</tr>
<tr>
<td></td>
<td>Note: The doses in this table provide approximately ZDV 4 mg/kg twice daily from birth to age 4 weeks.</td>
</tr>
<tr>
<td>Weight Band</td>
<td>Twice-Daily Volume of ZDV 10 mg/mL Syrup</td>
</tr>
<tr>
<td>2 kg to &lt;3 kg</td>
<td>1 mL</td>
</tr>
<tr>
<td>3 kg to &lt;4 kg</td>
<td>1.5 mL</td>
</tr>
<tr>
<td>4 kg to &lt;5 kg</td>
<td>2 mL</td>
</tr>
<tr>
<td>Aged &gt;4 Weeks:</td>
<td>ZDV 12 mg/kg twice daily</td>
</tr>
</tbody>
</table>

Selected Adverse Events

- Bone marrow suppression leading to anemia and neutropenia; macrocytosis with or without anemia.
- Nausea, vomiting, headache, insomnia, asthenia
- Lactic acidosis/severe hepatomegaly with hepatic steatosis
- Lipodystrophy and lipoatrophy
- Myopathy (associated with prolonged use of ZDV) and myositis

Special Instructions

- Give ZDV without regard to food.
- If substantial granulocytopenia or anemia develops in patients who are receiving ZDV, it may be necessary to discontinue therapy until bone marrow recovery is observed. In this setting, some patients may require erythropoietin or filgrastim injections or transfusions of red blood cells.
- Screen patients for hepatitis B virus (HBV) infection before using FDC products that contain lamivudine (3TC). Severe acute exacerbation of HBV infection can occur when 3TC is discontinued; therefore, hepatic...

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Downloaded from https://aidsinfo.nih.gov/guidelines on 4/30/2020
Infant (Aged \( \geq 35 \) Weeks Post-Conception and \( \geq 4 \) Weeks Post-Delivery, Weighing \( \geq 4 \) kg) and Child Dose

### Oral ZDV Dose

<table>
<thead>
<tr>
<th>Gestational Age at Birth</th>
<th>Oral ZDV Dose</th>
</tr>
</thead>
</table>
| \( \geq 30 \) weeks to <35 weeks | Birth to Age 2 Weeks:  
  • ZDV 2 mg/kg twice daily  
 Aged 2 Weeks to 6 to 8 Weeks:  
  • ZDV 3 mg/kg twice daily  
 Aged >6 Weeks to 8 Weeks:  
  • ZDV 12 mg/kg twice daily |
| <30 weeks | Birth to Age 4 Weeks:  
  • ZDV 2 mg/kg twice daily  
 Aged 4 Weeks to 8 to 10 Weeks:  
  • ZDV 3 mg/kg twice daily  
 Aged >8 Weeks to 10 Weeks:  
  • ZDV 12 mg/kg twice daily |

**Note:** For infants who are unable to tolerate oral agents, the intravenous dose should be 75% of the oral dose, but the dosing interval should remain the same.

### Weight-Based Dosing for Zidovudine

<table>
<thead>
<tr>
<th>Weight</th>
<th>Twice-Daily Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 kg to &lt;9 kg</td>
<td>12 mg/kg</td>
</tr>
<tr>
<td>9 kg to &lt;30 kg</td>
<td>9 mg/kg</td>
</tr>
<tr>
<td>( \geq 30 ) kg</td>
<td>300 mg</td>
</tr>
</tbody>
</table>

### Alternative Body Surface Area Dosing

**Oral:**

- ZDV 180 mg to 240 mg per m\(^2\) of body surface area every 12 hours

**Child and Adolescent (Weighing \( \geq 30 \) kg) and Adult Dose:**

- ZDV 300 mg twice daily

### [Combivir and Generic] Lamivudine/Zidovudine

**Child and Adolescent (Weighing \( \geq 30 \) kg) and Adult Dose:**

- One tablet twice daily

### [Trizivir and Generic] Abacavir/Lamivudine/Zidovudine

**Child and Adolescent (Weighing \( \geq 30 \) kg) and Adult Dose:**

- One tablet twice daily

---

**Metabolism/Elimination**

- ZDV is eliminated primarily by hepatic metabolism. The major metabolite is ZDV glucuronide, which is renally excreted.
- ZDV is phosphorylated intracellularly to active ZDV-triphosphate.

**Zidovudine Dosing in Patients with Renal Impairment:**

- A dose adjustment is required for ZDV in patients with renal insufficiency.

**Zidovudine Dosing in Patients with Hepatic Impairment:**

- The dose of ZDV may need to be reduced in patients with hepatic impairment.
- Do not use FDC products (e.g., Combivir, Trizivir) in patients with creatinine clearance <50 mL/min, patients who are on dialysis, or patients who have impaired hepatic function.

---

\(^a\) For premature infants who receive an HIV diagnosis, the time to change to the continuation dose varies with post-gestational age and clinical status of the infant.
Non-Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)

- Doravirine (DOR, Pifeltro)
- Efavirenz (EFV, Sustiva)
- Etravirine (ETR, Intelence)
- Nevirapine (NVP, Viramune)
- Rilpivirine (RPV, Edurant)
Doravirine (DOR, Pifeltro) (Last updated April 14, 2020; last reviewed April 14, 2020)

Formulations
Tablet: 100 mg

Fixed-Dose Combination Tablet:
• [Delstrigo] Doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg

When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

Dosing Recommendations
Child and Adolescent Dose:
• Doravirine (DOR) is not approved for use in children or adolescents aged <18 years.

Adult (Aged ≥18 Years) Dose:
• DOR 100 mg once daily in antiretroviral (ARV)-naive patients and ARV-experienced patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known mutations associated with resistance to DOR.

[Delstrigo] Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF)

Adult (Aged ≥18 Years) Dose:
• One tablet once daily in ARV-naive patients and ARV-experienced patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known mutations associated with resistance to DOR.

Selected Adverse Events
• Nausea
• Abdominal pain
• Diarrhea
• Abnormal dreams
• Insomnia, somnolence

Special Instructions
• DOR can be taken with or without food.
• Do not use DOR with other non-nucleoside reverse transcriptase inhibitors.
• When DOR is coadministered with rifabutin, the dose should be increased from DOR: 100 mg once daily to DOR 100 mg twice daily. When doravirine/lamivudine/TDF (DOR/3TC/TDF; Delstrigo) is coadministered with rifabutin, an additional 100-mg dose of freestanding DOR needs to be administered approximately 12 hours later.
• Screen patients for hepatitis B virus (HBV) infection before using Delstrigo, which contains 3TC and TDF. Severe acute exacerbation of HBV can occur when 3TC or TDF are discontinued; therefore, hepatic function and hepatitis B viral load should be monitored for several months after halting therapy with 3TC or TDF.

Metabolism/Elimination
• DOR is metabolized by the enzyme cytochrome P450 3A.
• DOR has multiple interactions with several drugs (see text below).
Doravirine Dosing in Patients with Hepatic Impairment:

- Dose adjustment is not required in patients with mild or moderate hepatic impairment. DOR has not been studied in patients with severe hepatic impairment.

Doravirine Dosing in Patients with Renal Impairment:

- Dose adjustment is not required when using DOR in patients with mild, moderate, or severe renal impairment. DOR use has not been studied in patients with end-stage renal disease or in patients on dialysis.
- DOR administered with 3TC and TDF as components of Delstrigo is not recommended in patients with estimated creatinine clearance <50 mL/min.
Efavirenz (EFV, Sustiva)  (Last updated April 14, 2020; last reviewed April 14, 2020)

Dosing Recommendations

**Neonatal Dose:**
- Efavirenz (EFV) is not approved for use in neonates.

**Pediatric Dose:**
- EFV capsules can be opened and the contents used as a sprinkle preparation for infants and children who are unable to swallow capsules.

*Infants and Children Aged 3 Months to <3 Years and Weighing ≥3.5 kg:*
- The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) does not recommend the use of EFV in children aged 3 months to <3 years due to highly variable pharmacokinetics in this age group.
- If the use of EFV is unavoidable due to a clinical situation, the Panel suggests using investigational doses of EFV in this age group (see Table A in the Pharmacokinetics and Dosing: Infants and Children Aged <3 Years section below). Evaluation of cytochrome P450 (CYP) 2B6 genotype is required prior to use of EFV in this age group. Therapeutic drug monitoring (TDM) should be used and EFV plasma concentration should be measured 2 weeks after initiation. If a child initiated

Selected Adverse Events

- Rash, which is generally mild and transient and appears to be more common in children than in adults
- Central nervous system (CNS) symptoms, such as fatigue, poor sleeping patterns, insomnia, vivid dreams, impaired concentration, agitation, seizures, depression, suicidal ideation, late-onset ataxia, and encephalopathy
- Use of EFV may produce false-positive results with some cannabinoid and benzodiazepine tests.
- Gynecomastia
- Hepatotoxicity
- Corrected QT prolongation

Special Instructions

- EFV capsules and tablets can be swallowed whole, or EFV capsules can be administered by sprinkling the contents of an opened capsule on food as described below.
- Bedtime dosing is recommended, particularly during the first 2 to 4 weeks of therapy, to improve tolerability of CNS side effects.
- Administer EFV, Atripla, Symfi, or Symfi Lo on an empty stomach. Avoid administration with
EFV at an investigational dose while aged <3 years, some experts would also measure EFV plasma concentration at age 3 years after the child transitions to the recommended dose for children aged ≥3 years (see the Therapeutic Drug Monitoring section below). When making a dose adjustment based on EFV concentrations, consultation with an expert in pediatric HIV infection is recommended.

Children Aged ≥3 Years and Weighing ≥10 kg:
Once-Daily Doses of Efavirenz by Weight

<table>
<thead>
<tr>
<th>Weight</th>
<th>EFV Dose¹,²</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 kg to &lt;15 kg</td>
<td>200 mg</td>
</tr>
<tr>
<td>15 kg to &lt;20 kg</td>
<td>250 mg</td>
</tr>
<tr>
<td>20 kg to &lt;25 kg</td>
<td>300 mg</td>
</tr>
<tr>
<td>25 kg to &lt;32.5 kg</td>
<td>350 mg</td>
</tr>
<tr>
<td>32.5 kg to &lt;40 kg</td>
<td>400 mg</td>
</tr>
<tr>
<td>≥40 kg</td>
<td>600 mg</td>
</tr>
</tbody>
</table>

¹ The dose in mg can be dispensed in any combination of capsule strengths. Capsules may be administered by sprinkling the contents onto an age-appropriate food (see Special Instructions).

² Some experts recommend a dose of EFV 367 mg per m² of body surface area (maximum dose 600 mg) due to concerns about underdosing at the upper end of each weight band (see the Pediatric Use section below for details). Weight bands approximate a dose of EFV 367 mg per m² of body surface area, with a maximum dose of 600 mg.

Instructions for Using the Efavirenz Capsule as a Sprinkle Preparation with Food or Formula:

- Hold capsule horizontally over a small container and carefully twist open to avoid spillage.
- Gently mix capsule contents with 1 to 2 teaspoons of an age-appropriate soft food (e.g., applesauce, grape jelly, yogurt) or reconstituted infant formula at room temperature.
- Administer within 30 minutes of mixing and do not consume additional food or formula for 2 hours after administration.

Metabolism/Elimination

- CYP2B6 is the primary enzyme for EFV metabolism.
- CYP3A and CYP2B6 inducer in vivo
- EFV is not recommended for patients with moderate or severe hepatic impairment.
- Interpatient variability in EFV exposure can be explained in part by polymorphisms in CYP450, particularly CYP2B6 polymorphisms. Slower metabolizers are at higher risk of toxicity (see the Therapeutic Drug Monitoring section below for information about the management of mild or moderate toxicity).

Atripla, Symfi, and Symfi Lo Dosing in Adults with Renal Impairment:

- Because these are FDC products, and because TDF, lamivudine, and emtricitabine require dose adjustments based on renal function, Atripla, Symfi, and Symfi Lo should not be used in patients with creatinine clearance <50 mL/min or in patients on dialysis.
Note: Symfi Lo has not been studied in children (sexual maturity ratings [SMRs] 1–3), and major interindividual variability in EFV plasma concentrations has been found in pediatric patients in a multiethnic setting. The 400 mg dose of EFV may be too low in children or adolescents with SMRs 1 to 3 who weigh ≥40 kg. The use of TDM is suggested by some Panel members when Symfi Lo is used in pediatric patients who weigh ≥40 kg (see the Therapeutic Drug Monitoring section below).
Etravirine (ETR, Intelence) (Last updated April 14, 2020; last reviewed April 14, 2020)

Formulations

Tablets: 25 mg, 100 mg, 200 mg

Dosing Recommendations

Neonate and Infant Dose:
• Etravirine (ETR) is not approved for use in neonates or infants.

Child Dose:
• ETR is not approved for use in children aged <2 years. Studies in infants and children aged 2 months to 2 years are under way.

Etravirine Dosing Table for Antiretroviral Therapy-Experienced Children and Adolescents Aged 2 to 18 Years and Weighing ≥10 kg

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>Twice-Daily Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 kg to &lt;20 kg</td>
<td>100 mg</td>
</tr>
<tr>
<td>20 kg to &lt;25 kg</td>
<td>125 mg</td>
</tr>
<tr>
<td>25 kg to &lt;30 kg</td>
<td>150 mg</td>
</tr>
<tr>
<td>≥30 kg</td>
<td>200 mg</td>
</tr>
</tbody>
</table>

Adult Dose for Antiretroviral Therapy-Experienced Patients:
• ETR 200 mg twice daily with food

Selected Adverse Events

• Nausea
• Diarrhea
• Rash, including Stevens-Johnson syndrome
• Hypersensitivity with rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure

Special Instructions

• ETR tablets are sensitive to moisture; store the tablets at room temperature in the original container with desiccant.

• Area under the curve of ETR is decreased by about 50% when the drug is taken on an empty stomach. Always administer ETR with food. The type of food does not affect ETR.

• Swallowing ETR tablets whole is the preferred means of administration and although the package insert contains instructions for dispersing ETR tablets in water or other liquids, using this administration method generally results in lower ETR exposures than swallowing tablets whole. Children who receive dispersed ETR tablets should switch to swallowing tablets whole as soon as they are able.

Metabolism/Elimination

• ETR is an inducer of cytochrome P450 (CYP) 3A4 and an inhibitor of CYP2C9, CYP2C19, and P-glycoprotein. It is a substrate for CYP3A4, CYP2C9, and CYP2C19.

• ETR is involved in multiple interactions with antiretroviral agents and other drugs (see text below).

Etravirine Dosing in Patients with Hepatic Impairment:
• No dose adjustment is required when using ETR in patients with mild or moderate
hepatic insufficiency. No dosing information is available for patients with severe hepatic impairment.

**Etravirine Dosing in Patients with Renal Impairment:**
- No dose adjustment is required when using ETR in patients with renal impairment.
Nevirapine (NVP, Viramune) *(Last updated April 14, 2020; last reviewed April 14, 2020)*

**Formulations**

**Oral Suspension:** 10 mg/mL  
**Tablets:** Immediate-release 200 mg tablets; extended-release (XR) 100 mg and 400 mg tablets  

**Generic Formulations:**  
- 10 mg/ml suspension  
- Immediate-release 200 mg tablets  
- XR 400 mg tablets  

The oral suspension formulation of brand-name nevirapine (Viramune) is not typically stocked in local pharmacies or hospitals. Have the pharmacy ask their drug wholesaler to order it from the Boehringer-Ingelheim distribution center. The distribution center should be able to ship the formulation directly to the pharmacy.

**Dosing Recommendations**

**Note:** Nevirapine (NVP) is often used to prevent perinatal transmission of HIV. See Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection.

**Child and Adolescent Dose:**  
- In most situations, NVP is given once daily for 2 weeks to allow for autoinduction of the enzymes involved in its metabolism. This may not be necessary in children aged <2 years.a  

**Immediate-Release Tablets and Oral Suspension**  
**Gestational Age of 34 to 37 Weeks:**  
- NVP 4 mg/kg per dose twice daily for the first week, increasing to NVP 6 mg/kg per dose twice daily thereafter (no lead-in dosing).a  
- This is an investigational dose that is not approved by the Food and Drug Administration (FDA).

**Gestational Age of >37 Weeks to Age of <1 Month:**  
- NVP 6 mg/kg per dose twice daily (no lead-in dosing).a  
- This is an investigational dose that is not approved by the FDA.  
- See Special Considerations for Dosing: Neonates and Premature Infants below.

**Aged ≥1 Month to <8 Years:**  
- NVP 200 mg per m² of body surface area per dose twice daily after lead-in dosing.a In children aged ≤2 years, some experts initiate NVP without lead-in dosing (maximum dose of immediate-release tablets is NVP 200 mg twice daily).

**Selected Adverse Events**

- Rash, including Stevens-Johnson syndrome  
- Symptomatic hepatitis, including fatal hepatic necrosisb  
- Severe systemic hypersensitivity syndrome with potential for multisystem organ involvement and shock

**Special Instructions**

- Shake the oral suspension well before administering and store at room temperature.  
- NVP can be given without regard to food.  
- NVP-associated skin rash usually occurs within the first 6 weeks of therapy. If rash occurs during the initial 14 day lead-in period, do not increase the dose until rash resolves (see Major Toxicities below).  
- Extended-release tablets must be swallowed whole. They cannot be crushed, chewed, or divided.  
- If NVP dosing is interrupted for >14 days, NVP should be restarted with once-daily dosing for 14 days, followed by escalation to the full, twice-daily regimen (see Dosing Considerations: Lead-In Requirement below).  
- Most cases of NVP-associated hepatic toxicity occur during the first 12 weeks of therapy; frequent clinical and laboratory monitoring, including liver function tests, is important during this period (see Major Toxicities below).
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Aged ≥8 Years:
- NVP 120 mg to 150 mg per m² of body surface area per dose twice daily after lead-in dosing (maximum dose of immediate-release tablets is NVP 200 mg twice daily).
- When adjusting the dose for a growing child, the mg dose need not be decreased as the child reaches age 8 years; rather, the mg dose can be left static to achieve the appropriate mg-per-m² dose as the child grows, as long as there are no adverse effects (AEs).

Extended-Release Tablets

Aged ≥6 Years:
- Patients aged ≥6 years who are already taking immediate-release NVP tablets twice daily can be switched to extended-release NVP tablets without lead-in dosing.a

Body Surface Area Dosing for Extended-Release Nevirapine Tablets

<table>
<thead>
<tr>
<th>Body Surface Area</th>
<th>Once-Daily Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.58 m² to 0.83 m²</td>
<td>NVP 200 mg (two 100-mg tablets)</td>
</tr>
<tr>
<td>0.84 m² to 1.16 m²</td>
<td>NVP 300 mg (three 100-mg tablets)</td>
</tr>
<tr>
<td>≥1.17 m²</td>
<td>NVP 400 mg (one 400-mg tablet)</td>
</tr>
</tbody>
</table>

Adolescent and Adult Dose:
- NVP 200 mg twice daily or NVP 400 mg with the extended-release tablets once daily after lead-in dosing.a,b

Nevirapine Used in Combination with Lopinavir/Ritonavir:
- A higher dose of lopinavir/ritonavir may be needed in patients who are also receiving NVP (see the Lopinavir/Ritonavir section for more information).

Metabolism/Elimination
- NVP is a substrate and inducer of cytochrome P450 (CYP) 3A4 and CYP2B6. More than 80% of a nevirapine dose is eliminated in urine as uridine diphosphate glucuronosyltransferase (UGT)-derived glucuronidated metabolites.

Nevirapine Dosing in Patients with Renal Failure Who Are Receiving Hemodialysis:
- An additional dose of NVP should be given following each dialysis session.

Nevirapine Dosing in Patients with Hepatic Impairment:
- NVP should not be administered to patients with moderate or severe hepatic impairment.

---

a NVP is usually initiated at a lower dose that is increased in a stepwise fashion. NVP induces CYP metabolizing enzymes, which results in increased drug clearance. The stepwise increase in dose decreases the occurrence of rash. Clinicians should initiate therapy with the immediate-release tablet formulation once daily instead of twice daily for the first 14 days of therapy. If there are no rashes or other AEs after 14 days of therapy, increase the dose of NVP to the age-appropriate full dose of the immediate-release tablet formulation administered twice daily. For example, the recommended oral dose for pediatric patients aged ≥1 month to <8 years is NVP 200 mg per m² of body surface area once daily for the first 14 days, followed by NVP 200 mg per m² of body surface area twice daily thereafter. However, in children aged ≥2 years, some experts initiate NVP without lead-in dosing (see Dosing Considerations: Lead-In Requirement and Special Considerations for Dosing: Neonates and Premature Infants below). In patients who are already receiving the full, twice-daily dose of the immediate-release tablets, extended-release tablets can be used without the lead-in period. Patients must swallow extended-release tablets whole. They must not be chewed, crushed, or divided. Patients must never take more than one form of NVP at the same time. The dose should not exceed NVP 400 mg daily.

b Severe, life-threatening, and, in rare cases, fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis, and hepatic failure, have occurred in patients who were taking NVP. These toxicities are less common in children than adults. The majority of cases occur during the first 12 weeks of therapy and may be associated with rash or other signs or symptoms of hypersensitivity reaction (HSR). NVP should be discontinued and not restarted in children or adults who develop symptomatic hepatitis, severe transaminase elevations, or HSRS.
Rilpivirine (RPV, Edurant) *(Last updated April 14, 2020; last reviewed April 14, 2020)*

**Formulations**

**Tablets:** 25 mg

**Fixed-Dose Combination Tablets:**
- [Complera] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir disoproxil fumarate 300 mg
- [Juluca] Dolutegravir 50 mg/rilpivirine 25 mg
- [Odefsey] Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg

> When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

**Dosing Recommendations**

**Neonate and Infant Dose:**
- Rilpivirine (RPV) is not approved for use in neonates or infants.

**Children Aged <12 Years:**
- RPV is not approved for use in children aged <12 years (for more information, see the Pharmacokinetics section below).

**Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose:**
- RPV 25 mg once daily with a meal in antiretroviral therapy (ART)-naive patients who have HIV RNA ≤100,000 copies/mL or in patients who are virologically suppressed (HIV RNA <50 copies/mL) with no history of virologic failure or resistance to RPV and other antiretroviral (ARV) drugs in the new regimen.

**[Complera] Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (TDF)**

**Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose:**
- One tablet once daily with a meal in ART-naive patients with baseline viral loads ≤100,000 copies/mL. One tablet once daily can also be used to replace the current ARV regimen in patients who are currently on their first or second regimen and who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Complera.

**Selected Adverse Events**

- Depression
- Insomnia
- Headache
- Rash (can be severe and include drug reaction [or rash] with eosinophilia and systemic symptoms)
- Hepatotoxicity
- Altered adrenocorticotropic hormone stimulation test of uncertain clinical significance

**Special Instructions**

- Do not start RPV in patients with HIV RNA >100,000 copies/mL due to increased risk of virologic failure.
- Patients must be able to take RPV with a meal of at least 500 calories on a regular schedule (a protein drink alone does not constitute a meal).
- Do not use RPV with other non-nucleoside reverse transcriptase inhibitors.
- Do not use RPV with proton pump inhibitors (e.g., omeprazole, pantoprazole).
- Antacids should only be taken at least 2 hours before or at least 4 hours after RPV.
- H2 receptor antagonists (e.g., cimetidine, famotidine) should only be administered at least 12 hours before or at least 4 hours after RPV.
- Use RPV with caution when coadministering it with a drug that has a known risk of
**[Juluca] Dolutegravir/Rilpivirine**

**Adult Dose:**
- One tablet once daily with a meal as a complete regimen to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Juluca.
- Not approved for use in children or adolescents (see Simplification of Treatment section below).

**[Odefsey] Emtricitabine/Rilpivirine/Tenofovir Alafenamide (TAF)**

**Child and Adolescent (Aged ≥12 Years and Weighing ≥35 kg) and Adult Dose:**
- One tablet once daily with a meal in ART-naive patients with HIV RNA ≤100,000 copies/mL. One tablet once daily can also be used to replace a stable ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Odefsey.

**Metabolism/Elimination**
- Cytochrome P450 (CYP) 3A substrate.

**Rilpivirine Dosing in Patients with Hepatic Impairment:**
- No dose adjustment is necessary in patients with mild or moderate hepatic impairment.
- RPV decreases tubular secretion of creatinine and slightly increases measured serum creatinine, but it does not affect glomerular filtration.

**Rilpivirine Dosing in Patients with Renal Impairment:**
- No dose adjustment is necessary in patients with mild or moderate renal impairment.
- However, RPV should be used with caution in patients with severe renal impairment or end-stage renal disease. These patients should be monitored more frequently for adverse events; renal dysfunction may alter drug absorption, distribution, and metabolism, leading to increased RPV concentrations.
- The FDC tablet Complera should not be used in patients with creatinine clearance (CrCl) <50 mL/min, and the FDC tablet Odefsey should not be used in patients with CrCl <30 mL/min.
- When using Complera, see the TDF section of the guidelines; when using Odefsey, see the TAF section.

Torsades de Pointes (for more information, see CredibleMeds).
Protease Inhibitors (PIs)
Atazanavir (ATV, Reyataz)
Darunavir (DRV, Prezista)
Lopinavir/Ritonavir (LPV/r, Kaletra)
**Atazanavir (ATV, Reyataz)**  
*(Last updated April 14, 2020; last reviewed April 14, 2020)*

### Formulations

- **Powder Packet:** 50 mg/packet
- **Capsules:** 150 mg, 200 mg, and 300 mg

### Generic Formulations

- 150 mg, 200 mg, and 300 mg capsules

### Fixed-Dose Combination Tablets:

- [Evotaz] Atazanavir 300 mg/cobicistat 150 mg

Capsules and powder packets are not interchangeable.

### Dosing Recommendations

#### Neonate:

- Atazanavir (ATV) is not approved for use in neonates and infants aged <3 months. **ATV should not be administered** to neonates due to risks associated with hyperbilirubinemia (e.g., bilirubin-induced neurologic dysfunction).

#### Infant and Child Dose

*Powder Formulation of Atazanavir:*^\(^a\)

- The powder formulation of ATV must be administered with ritonavir (RTV).
- The powder formulation is not approved for use in infants aged <3 months or weighing <5 kg.

#### Atazanavir Powder Dosing Table for Infants and Children Aged ≥3 Months and Weighing ≥5 kg^\(^a\)

<table>
<thead>
<tr>
<th>Weight</th>
<th>Once-Daily Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 kg to &lt;15 kg</td>
<td>ATV 200 mg (four packets) plus RTV 80 mg (1 mL oral solution), with food</td>
</tr>
<tr>
<td>15 kg to &lt;25 kg</td>
<td>ATV 250 mg (five packets) plus RTV 80 mg (1 mL oral solution), both with food</td>
</tr>
</tbody>
</table>

*Capsule Formulation of Atazanavir:*^\(^a\)

- ATV capsules are not approved for use in children aged <6 years or weighing <15 kg.

#### Atazanavir Capsule Dosing Table for Children and Adolescents Aged ≥6 Years and Weighing ≥15 kg

<table>
<thead>
<tr>
<th>Weight</th>
<th>Once-Daily Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;15 kg</td>
<td>Capsules not recommended</td>
</tr>
<tr>
<td>15 kg to &lt;35 kg</td>
<td>ATV/r 200 mg/100 mg, both with food</td>
</tr>
<tr>
<td>≥35 kg</td>
<td>ATV/r 300 mg/100 mg, both with food</td>
</tr>
</tbody>
</table>

### Selected Adverse Events

- Indirect hyperbilirubinemia
- Prolonged electrocardiogram PR interval, first-degree symptomatic atroventricular block in some patients
- Nephrolithiasis
- Increased serum transaminases
- Hyperlipidemia (occurs primarily with RTV boosting)

### Special Instructions

- Administer ATV with food to enhance absorption.
- Capsules and powder packets are not interchangeable.
- Do not open capsules.
- Because ATV can prolong the PR interval of the electrocardiogram, use ATV with caution in patients with pre-existing cardiac conduction system disease or with other drugs that are known to prolong the PR interval (e.g., calcium channel blockers, beta-blockers, digoxin, verapamil).

- ATV absorption is dependent on low gastric pH; therefore, when ATV is administered with medications that alter gastric pH, dosing adjustments may be indicated (see the Drug Interactions section in the ATV package insert).

- The plasma concentration, and therefore the therapeutic effect, of ATV can be expected to decrease substantially when ATV is coadministered with proton-pump inhibitors (PPIs). Antiretroviral therapy (ART)-naive patients who are receiving any PPI should receive a dose of that PPI that is equivalent...
ART-Naive Patients Who Are Unable to Tolerate Ritonavir
Child and Adolescent (Aged ≥13 Years and Weighing ≥40 kg) and Adult Dose:

- ATV 400 mg (capsule formulation only) once daily with food
- ATV powder is not an option, since it must be administered with RTV.
- For the capsule formulation, while the Food and Drug Administration (FDA) does not recommend the use of unboosted ATV in children aged <13 years, adolescents aged ≥13 years and weighing ≥40 kg may be prescribed unboosted ATV if they are not concurrently taking tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF).
- In order to achieve target drug concentrations, adolescents may require doses of ATV that are higher than those recommended for use in adults (see Pediatric Use below).
- The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV does not recommend the use of unboosted ATV.

ART-Naive and ART-Experienced Patients
Child and Adolescent (Weighing ≥35 kg) and Adult Dose:

- Atazanavir/ritonavir (ATV/r) 300 mg/100 mg once daily with food
- Atazanavir/cobicistat (ATV/c) 300 mg/150 mg once daily with food, administered as single agents simultaneously or as the coformulated drug Evotaz

- Both ATV/r and ATV/c must be used in combination with other antiretroviral drugs.

[Evotaz] Atazanavir/Cobicistat
Child and Adolescent (Weighing ≥35 kg) and Adult Dose:

- One tablet once daily with food

Patients with hepatitis B virus or hepatitis C virus infections and patients who had marked elevations in transaminase levels before treatment may have an increased risk of further elevations in transaminase levels or hepatic decompensation.

- ATV oral powder contains phenylalanine, which can be harmful to patients with phenylketonuria. Each packet of oral powder contains 35 mg of phenylalanine.

Powder Administration:

- Mix ATV oral powder with at least 1 tablespoon of soft food (e.g., applesauce, yogurt). Oral powder mixed with a beverage (at least 30 mL of milk or water) may be used for older infants who can drink from a cup. For young infants (aged <6 months) who cannot eat solid food or drink from a cup, oral powder should be mixed with at least 10 mL of infant formula and given using an oral dosing syringe.
- Administer RTV immediately following powder administration.
- Administer the entire dose of oral powder within 1 hour of preparation.

Metabolism/Elimination

- ATV is a substrate and inhibitor of cytochrome P450 (CYP) 3A4 and an inhibitor of CYP1A2, CYP2C9, and uridine diphosphate glucuronyl transferase 1A1.

Atazanavir Dosing in Patients with Hepatic Impairment:

- ATV should be used with caution in patients with mild or moderate hepatic impairment. Consult the manufacturer’s prescribing information for the dose adjustment in patients with moderate impairment.
- ATV should not be used in patients with severe hepatic impairment.

Atazanavir Dosing in Patients with Renal Impairment:

- No dose adjustment is required for patients with renal impairment.
- ATV should not be given to ART-experienced patients with end-stage renal disease who are on hemodialysis.
mg/kg dosing is higher for the ATV powder packets than for the capsules. In P1020A, children of similar age and size who were taking ATV powder had lower exposures than those who were taking ATV capsules.

Children weighing ≥25 kg who cannot swallow ATV capsules may receive ATV 300 mg oral powder (six packets) plus RTV 100 mg oral solution, both administered once daily with food.

Either RTV capsules or RTV oral solution can be used.

Adult patients who cannot swallow capsules may take ATV oral powder once daily with food using the adult dose for the capsules. ATV oral powder should be administered with RTV.

See the Cobicistat section for important information about toxicity, drug interactions, and monitoring of patients who receive cobicistat (COBI) and the combination of COBI and TDF.
**Darunavir (DRV, Prezista)** *(Last updated April 14, 2020; last reviewed April 14, 2020)*

### Formulations

**Oral Suspension:** 100 mg/mL  
**Tablets:** 75 mg, 150 mg, 600 mg, 800 mg  
**Fixed-Dose Combination Tablets:**  
- [Prezobix] Darunavir 800 mg/cobicistat 150 mg  
- [Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg

When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

### Dosing Recommendations

**Note:** Darunavir (DRV) should not be used without a pharmacokinetic (PK) enhancer (boosting agent). Ritonavir (RTV) may be used as the boosting agent in children and adults. Cobicistat (COBI) may be used as a boosting agent with DRV in children weighing ≥40 kg and in adults.

**Neonate/Infant Dose:**  
- DRV is not approved for use in neonates/infants.

**Child Dose**  
**Aged <3 Years:**  
- **Do not use DRV in children aged <3 years or weighing ≤10 kg.** In juvenile rats, DRV caused convulsions and death, and these events have been attributed to immaturity of the blood-brain barrier and liver metabolic pathways.

**Aged ≥3 Years to <12 Years:**  
- Dosing recommendations in the table below are for children aged ≥3 years to <12 years and weighing ≥10 kg who are antiretroviral therapy (ART)-naive or treatment-experienced and with or without resistance testing results that demonstrate that they have at least one mutation that is associated with DRV resistance.

### Selected Adverse Events

- Skin rash, including Stevens-Johnson syndrome and erythema multiforme
- Hepatotoxicity
- Diarrhea, nausea
- Headache
- Hyperlipidemia, transaminase elevation, hyperglycemia
- Fat maldistribution

### Special Instructions

- Once-daily DRV is not generally recommended for use in children aged <12 years or weighing <40 kg. Dosing estimates for these patients were based on limited data, and there is limited clinical experience with this dosing schedule in this age group.
- Once-daily DRV should not be used if any one of the following resistance-associated mutations are present: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, or L89V.
- DRV must be administered with food, which increases DRV plasma concentrations by 30%.
- DRV contains a sulfonamide moiety. Use DRV with caution in patients with known sulfonamide allergies.
- Pediatric dosing requires coadministration of tablets with different strengths to achieve the
Twice Daily Darunavir and Ritonavir Doses for Children Aged 3 Years to <12 Years and Weighing ≥10 kg

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose (Twice Daily with Food)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 kg to &lt;11 kg</td>
<td>DRV 200 mg (2.0 mL) plus RTV 32 mg (0.4 mL)</td>
</tr>
<tr>
<td>11 kg to &lt;12 kg</td>
<td>DRV 220 mg (2.2 mL) plus RTV 32 mg (0.4 mL)</td>
</tr>
<tr>
<td>12 kg to &lt;13 kg</td>
<td>DRV 240 mg (2.4 mL) plus RTV 40 mg (0.5 mL)</td>
</tr>
<tr>
<td>13 kg to &lt;14 kg</td>
<td>DRV 260 mg (2.6 mL) plus RTV 40 mg (0.5 mL)</td>
</tr>
<tr>
<td>14 kg to &lt;15 kg</td>
<td>DRV 280 mg (2.8 mL) plus RTV 48 mg (0.6 mL)</td>
</tr>
<tr>
<td>15 kg to &lt;30 kg</td>
<td>DRV 375 mg (combination of tablets or 3.8 mL) plus RTV 48 mg (0.6 mL)</td>
</tr>
<tr>
<td>30 kg to &lt;40 kg</td>
<td>DRV 450 mg (combination of tablets or 4.6 mL) plus RTV (100 mg tablet or powder or 1.25 mL)</td>
</tr>
<tr>
<td>≥40 kg</td>
<td>DRV 600 mg (tablet or 6 mL) plus RTV 100 mg (tablet or 1.25 mL)</td>
</tr>
</tbody>
</table>

**Child and Adolescent (Aged ≥12 Years and Weighing ≥30 to <40 kg) Dose for Treatment-Naive or Treatment-Experienced Patients with or Without at Least One Mutation Associated With Darunavir Resistance:**
- DRV 450 mg (using a combination of tablets) plus RTV 100 mg, both **twice daily with food**

**Child and Adolescent (Aged ≥12 years and Weighing ≥40 kg)** and **Adult Dose for Treatment-Naive or Treatment-Experienced Patients with No Mutations Associated With Darunavir Resistance:**
- DRV 800 mg (using a tablet or combination of tablets) plus RTV 100 mg **once daily with food**

**Child and Adolescent (Weighing ≥40 kg) and Adult Dose for Treatment-Naive or Treatment-Experienced Patients with No Mutations Associated with Darunavir Resistance:**
- DRV 800 mg (tablet) plus COBI! 150 mg (tablet) or the coformulation Prezcobix **once daily with food**

**Child and Adolescent (Weighing ≥40 kg) and Adult Dose for Treatment-Experienced Patients with at Least One Mutation Associated with Darunavir Resistance:**
- DRV 600 mg plus RTV 100 mg, both **twice daily with food**
- The use of COBI is **not recommended** with DRV 600 mg twice daily.

---

**Metabolism/Elimination**
- Cytochrome P450 3A4 substrate and inhibitor.

**Darunavir Dosing in Patients with Hepatic Impairment:**
- DRV is primarily metabolized by the liver. Caution should be used when administering DRV to patients with hepatic impairment. DRV is **not recommended** in patients with severe hepatic impairment.

**Darunavir Dosing in Patients with Renal Impairment:**
- No dose adjustment is required in patients with moderate renal impairment (creatinine clearance 30–60 mL/min).
[Prezcobix] Darunavir/Cobicistat

**Child and Adolescent (Weighing ≥40 kg) and Adult Dose for Treatment-Naive or Treatment-Experienced Patients with No Mutations Associated with Darunavir Resistance:**

- One tablet once daily with food

[Symtuza] Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (TAF)

**Child and Adolescent (Weighing ≥40 kg) and Adult Dose:**

- One tablet once daily with food in ARV-naive patients or in patients who have been virologically suppressed (HIV RNA <50 copies/mL) for at least 6 months with no known mutations associated with resistance to DRV or tenofovir.

---

a Once-daily dosing of DRV is approved by the Food and Drug Administration (FDA), but the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) does not generally recommend using this dosing schedule in children (see Frequency of Administration below).

b Note that the dose in children weighing 10 kg to 15 kg is DRV 20 mg/kg plus RTV 3 mg/kg of body weight per dose, which is higher than the weight-adjusted dose in children with higher weights.

c RTV 80 g/mL oral solution.

d The volumes for the 375-mg and 450-mg DRV doses are rounded for suspension-dose convenience.

e Some Panel members recommend using the FDA-approved dose of once-daily DRV 675 mg (administered using a combination of tablets) plus RTV 100 mg once daily for adolescents weighing ≥30 kg to <40 kg (see Table B below).

f See the Cobicistat section for important information about toxicity, drug interactions, and monitoring in patients who receive COBI.
Lopinavir/Ritonavir (LPV/r, Kaletra)  (Last updated April 14, 2020; last reviewed April 14, 2020)

Formulations

Oral Solution:
• [Kaletra] Lopinavir 80 mg/mL and ritonavir 20 mg/mL (contains 42.4% alcohol by volume and 15.3% propylene glycol by weight/volume)

Film-Coated Tablets:
• [Kaletra] Lopinavir 100 mg/ritonavir 25 mg
• [Kaletra] Lopinavir 200 mg/ritonavir 50 mg

For additional information, see Drugs@FDA or DailyMed.

Dosing Recommendations

Neonate (Aged <14 Days) Dose:
• Lopinavir/ritonavir (LPV/r) is not approved by the Food and Drug Administration (FDA) for use in neonates before a postmenstrual age of 42 weeks and a postnatal age of at least 14 days. However, when no alternatives are available for neonates who have not met these age thresholds, some members of the Panel would consider using LPV/r oral solution at a dose of 300 mg/75 mg per m² of body surface area per dose twice daily in combination with careful monitoring of serum osmolality, serum creatinine, liver function enzymes, cardiac function, and electrolytes. This use of LPV/r is based on limited research and clinical experience. The potential benefit of using LPV/r in premature infants must be carefully balanced with the risk of metabolic and cardiac toxicity.

Dosing for Individuals Who Are Not Receiving Concomitant Nevirapine, Efavirenz, Fosamprenavir, or Nelfinavir

Infant (Aged 14 Days–12 Months) Dose:
• Once-daily dosing is not recommended.
• LPV/r 300 mg/75 mg per m² of body surface area per dose twice daily. This approximates LPV/r 16 mg/4 mg (both per kg body weight) twice daily. Use of this dose in infants aged <12 months is associated with lower LPV trough levels than those found in adults; LPV dosing should be adjusted for growth at frequent intervals (see text below). Also see text for information on transitioning infants to the lower mg per m² dose.

Selected Adverse Events

• Gastrointestinal (GI) intolerance, nausea, vomiting, diarrhea, alteration of taste
• Hyperlipidemia, especially hypertriglyceridemia
• Elevated transaminases
• Hyperglycemia
• PR interval prolongation
• QT interval prolongation and Torsades de Pointes
• Risk of toxicity—including life-threatening cardiotoxicity—is increased in premature infants (see Major Toxicities below).

Special Instructions

• LPV/r tablets can be administered without regard to food; administration with or after meals may enhance GI tolerability.
• LPV/r tablets must be swallowed whole. Do not crush or split tablets.
• LPV/r oral solution should be administered with food, because a high-fat meal increases absorption.
• The poor palatability of LPV/r oral solution is difficult to mask with flavorings or foods (see Formulations).
• LPV/r oral solution can be kept at room temperature (up to 77°F or 25°C) if used within 2 months. If kept refrigerated (36°F to 46°F or 2°C to 8°C), LPV/r oral solution remains stable until the expiration date printed on the label.
• Children aged <18 years who receive once-daily dosing of LPV/r have shown...
Child and Adolescent (Aged >12 Months to 18 Years) Dose:

- Once-daily dosing is not recommended.
- LPV/r 300 mg/75 mg per m² of body surface area per dose twice daily (maximum dose LPV/r 400 mg/100 mg twice daily, except as noted below). For patients weighing <15 kg, this approximates LPV/r 13 mg/3.25 mg (both per kg body weight) twice daily. For patients weighing ≥15 kg to 45 kg, this dose approximates LPV/r 11 mg/2.75 mg (both per kg body weight) twice daily. This dose is routinely used by many clinicians and is the preferred dose for antiretroviral therapy (ART)-experienced patients who could harbor virus with decreased LPV susceptibility (see text below).

- LPV/r 230 mg/57.5 mg per m² of body surface area per dose twice daily can be used in antiretroviral (ARV)-naive patients aged >1 year. For patients weighing <15 kg, this dose approximates LPV/r 12 mg/3 mg per kg body weight given twice daily. For patients weighing ≥15 kg to 40 kg, this dose approximates LPV/r 10 mg/2.5 mg per kg body weight given twice daily. This lower dose should not be used in treatment-experienced patients who could harbor virus with decreased LPV susceptibility.

Weight-Band Dosing for Lopinavir 100 mg/Ritonavir 25 mg Pediatric Tablets in Children and Adolescents

<table>
<thead>
<tr>
<th>Dosing Target</th>
<th>Recommended Number of LPV/r 100 mg/25 mg Tablets Given Twice Daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body Weight</td>
<td></td>
</tr>
<tr>
<td>15 kg to 20 kg</td>
<td>300 mg/m² per dose given twice daily</td>
</tr>
<tr>
<td>&gt;20 kg to 25 kg</td>
<td>230 mg/m² per dose given twice daily</td>
</tr>
<tr>
<td>&gt;25 kg to 30 kg</td>
<td></td>
</tr>
<tr>
<td>&gt;30 kg to 35 kg</td>
<td></td>
</tr>
<tr>
<td>&gt;35 kg to 45 kg</td>
<td></td>
</tr>
<tr>
<td>&gt;45 kg</td>
<td>4² or 5³</td>
</tr>
</tbody>
</table>

a Two tablets that each contain LPV/r 200 mg/50 mg can be substituted for the four LPV/r 100 mg/25 mg tablets in children who are capable of swallowing a larger tablet.

b In patients who weigh >45 kg and who are receiving concomitant nevirapine (NVP), efavirenz (EFV), fosamprenavir (FPV), or nelfinavir (NFV), the FDA-approved adult dose is LPV/r 500 mg/125 mg twice daily, given as a combination of two tablets of LPV/r 200 mg/50 mg and one tablet of LPV/r 100 mg/25 mg. Alternatively, three tablets of LPV/r 200 mg/50 mg can be used for ease of dosing.

Considerable variability in plasma concentrations and have a higher incidence of diarrhea. Therefore, once-daily dosing is not recommended for this age group.

- Use of LPV/r once daily is contraindicated if three or more of the following LPV resistance-associated substitutions are present: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. This is because higher LPV trough concentrations may be required to suppress resistant virus.

Metabolism/Elimination

- Cytochrome P450 3A4 substrate and inhibitor.

Lopinavir/Ritonavir Dosing in Patients with Hepatic Impairment:

- LPV/r is primarily metabolized by the liver. Use caution when administering LPV to patients with hepatic impairment. No dosing information is currently available for children or adults with hepatic insufficiency.

- In the coformulation of LPV/r, ritonavir acts as a pharmacokinetic enhancer, not as an ARV agent. It does this by inhibiting the metabolism of LPV and increasing LPV plasma concentrations.
Adult (Aged >18 Years) Dose:
- LPV/r 800 mg/200 mg once daily; or
- LPV/r 400 mg/100 mg twice daily
- Do not use once-daily dosing in children; adolescents; in patients receiving concomitant therapy with NVP, EFV, FPV, or NFV; or in patients with three or more LPV-associated mutations (see Special Instructions for a list of mutations).

Dosing for Individuals with Three or More Lopinavir-Associated Mutations (See Special Instructions for List):
- LPV/r 400 mg/100 mg twice daily

Dosing for Individuals Receiving Concomitant Nevirapine or Efavirenz:
- These drugs induce LPV metabolism and reduce LPV plasma levels. Increased LPV/r dosing is required with concomitant administration of these drugs. Once-daily dosing should not be used in these patients.

Child and Adolescent (Aged >12 Months to 18 Years) Dose:
- LPV/r 300 mg/75 mg per m² of body surface area per dose twice daily. See table for weight-band dosing when using tablets.

Adult (Aged >18 Years) Dose:
- The FDA-approved dose is LPV/r 500 mg/125 mg twice daily, given as a combination of two tablets of LPV/r 200 mg/50 mg and one tablet of LPV/r 100 mg/25 mg. Alternatively, three tablets of LPV/r 200 mg/50 mg can be used for ease of dosing. Once-daily dosing should not be used.

Lopinavir/Ritonavir Used in Combination with Maraviroc
- Maraviroc doses may need modification (see the Maraviroc section for more information).
Entry and Fusion Inhibitors

Ibalizumab (IBA, Trogarzo)
Maraviroc (MVC, Selzentry)
## Ibalizumab (IBA, Trogarzo) (Last updated April 14, 2020; last reviewed April 14, 2020)

### Formulations

**Single-Dose Vial for Intravenous Administration:** 200 mg/1.33 mL (150 mg/mL) in a single-dose vial. Each single-dose vial contains the following inactive ingredients: L-histidine, polysorbate 80, sodium chloride, and sucrose.

### Dosing Recommendations

**Child and Adolescent Dose:**
- The safety and efficacy of using ibalizumab (IBA) in children and adolescents has not been established.

**Adult Dose:**
- A single loading dose infusion of IBA 2,000 mg administered intravenously (IV) over 30 minutes is followed by a maintenance dose of IBA 800 mg administered IV over 15 minutes every 2 weeks.
- Food and Drug Administration approval of IBA is limited to heavily treatment-experienced adults with multidrug-resistant HIV infection who are experiencing treatment failure on their current regimen.
- IBA is used in combination with other antiretroviral drugs.

### Selected Adverse Events

- Diarrhea, dizziness, nausea, rash
- Immune reconstitution inflammatory syndrome
- Potential for immunogenicity in the form of anti-IBA antibodies

### Special Instructions

- The solution in the vial has to be diluted in 0.9% Sodium Chloride Injection and administered by IV infusion.
- Using aseptic technique, withdraw 1.33 mL from each vial and transfer into a 250 mL bag of 0.9% sodium chloride for IV injection. Other IV diluents must not be used.
- Once diluted, the solution should be administered immediately. If not used immediately, the solution can be stored at room temperature for up to 4 hours or refrigerated for up to 24 hours. Refrigerated solution should be allowed to stand at room temperature for at least 30 minutes but no more than 4 hours prior to administration.
- Diluted solution is administered as an IV infusion, not as a bolus or IV push.

### Metabolism/Elimination

- Monoclonal antibodies are metabolized to peptides and amino acids.
Maraviroc (MVC, Selzentry)  

Formulations

Oral Solution: 20 mg/mL
Tablets: 25 mg, 75 mg, 150 mg, 300 mg

Dosing Recommendations

Neonate and Infant Dose:
- Maraviroc (MVC) is not approved by the Food and Drug Administration (FDA) for use in neonates or infants.

Pediatric Dose:
- MVC is approved by the FDA for use in ART-experienced children aged ≥2 years and weighing ≥10 kg who have CCR5-tropic HIV-1.

Recommended Maraviroc Dose for Treatment-Experienced Children Aged ≥2 Years and Weighing ≥10 kg: Tablets or Oral Solution

<table>
<thead>
<tr>
<th>Weight Band</th>
<th>Twice-Daily Dosing</th>
<th>Oral Solution 20 mg/mL</th>
<th>Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 kg to &lt;20 kg</td>
<td>50 mg</td>
<td>2.5 mL</td>
<td>Two 25-mg tablets</td>
</tr>
<tr>
<td>20 kg to &lt;30 kg</td>
<td>75 mg to 80 mg</td>
<td>4 mL</td>
<td>One 75-mg tablet</td>
</tr>
<tr>
<td>30 kg to &lt;40 kg</td>
<td>100 mg</td>
<td>5 mL</td>
<td>One 25-mg tablet and one 75-mg tablet</td>
</tr>
<tr>
<td>≥40 kg</td>
<td>150 mg</td>
<td>7.5 mL</td>
<td>One 150-mg tablet</td>
</tr>
</tbody>
</table>

Selected Adverse Events

- Nausea, vomiting
- Abdominal pain, diarrhea
- Cough
- Upper respiratory tract infections
- Fever
- Rash
- Hepatotoxicity (which may be preceded by severe rash and/or other signs of systemic allergic reaction)
- Postural hypotension (generally seen in patients with severe renal insufficiency)
- Dizziness

Special Instructions

- MVC is recommended for use in patients who only have CCR5-tropic HIV-1. Before using MVC, conduct testing with an HIV tropism assay (see Drug-Resistance Testing in the Adult and Adolescent Antiretroviral Guidelines) to exclude the presence of CXCR4-tropic or mixed/dual-tropic HIV. Do not use MVC if CXCR4-tropic or mixed/dual-tropic HIV is present.
- MVC can be given without regard to food.
- Instruct patients on how to recognize symptoms of allergic reactions or hepatitis.
- Use caution when administering MVC to patients with underlying cardiac disease.

Metabolism/Elimination

- MVC is a substrate of CYP3A4. If a patient is receiving antiretroviral agents or other medications that act as CYP3A inducers or inhibitors, the dose of MVC should be adjusted accordingly.

Maraviroc Dosing in Patients with Hepatic Impairment:
- Use caution when administering MVC to patients with hepatic impairment; MVC concentrations may be increased in these patients.
### Recommended Maraviroc Dose for Adults: Tablets

<table>
<thead>
<tr>
<th>When Coadministered With:</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potent CYP3A inhibitors (with or without a potent CYP3A inducer), including all PIs except TPV/r</td>
<td>150 mg twice daily</td>
</tr>
<tr>
<td>Non-interacting concomitant medications, including NRTIs, T-20, TPV/r, NVP, and RAL</td>
<td>300 mg twice daily</td>
</tr>
<tr>
<td>Potent CYP3A inducers (without a potent CYP3A inhibitor), including EFV and ETR</td>
<td>600 mg twice daily</td>
</tr>
</tbody>
</table>

### Maraviroc Dosing in Patients with Renal Impairment:

- There are no data to recommend specific doses of MVC for pediatric patients with mild or moderate renal impairment. MVC is **contraindicated** for pediatric patients with severe renal impairment or end-stage renal disease who are on regular hemodialysis and who are receiving potent CYP3A inhibitors.
- Refer to the manufacturer’s prescribing information for the appropriate doses to use in adult patients with renal impairment.
**Integrase Inhibitors**

- Bictegravir (BIC)
- Dolutegravir (DTG, Tivicay)
- Elvitegravir (EVG)
- Raltegravir (RAL, Isentress)
Bictegravir (BIC)  (Last updated April 14, 2020; last reviewed April 14, 2020)

Formulations
Bictegravir is only available in a fixed-dose combination (FDC) tablet.

Fixed-Dose Combination Tablet:
- [Biktarvy] Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg

When using FDC tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

Dosing Recommendations
[Biktarvy] Bictegravir/Emtricitabine/Tenofovir Alafenamide (TAF)

Child (Weighing <25 kg) Dose:
- There are currently no data available on the appropriate dose of Biktarvy in children aged <6 years and weighing <25 kg. Studies are currently being conducted to identify the appropriate dose for this age and weight group.

Child and Adolescent (Weighing ≥25 kg) and Adult Dose:
- One tablet once daily with or without food in antiretroviral therapy-naive patients. This dose of Biktarvy can also be used to replace the current antiretroviral (ARV) regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 3 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Biktarvy.

Selected Adverse Events
- Diarrhea, nausea, headache

Special Instructions
- Administer Biktarvy with or without food. See Drug Interactions below for guidance when administering Biktarvy with antacids or iron or calcium supplements.
- Screen patients for hepatitis B virus (HBV) infection before using emtricitabine (FTC) or TAF. Severe acute exacerbation of HBV can occur when discontinuing FTC or TAF; therefore, monitor hepatic function for several months after halting therapy with FTC or TAF.
- Biktarvy is not recommended for use with other ARV drugs.

Metabolism/Elimination
- Bictegravir is metabolized by cytochrome P450 3A4 and uridine diphosphate glucuronosyltransferase 1A1.

Biktarvy Dosing in Patients with Hepatic Impairment:
- Biktarvy is not recommended for use in patients with severe hepatic impairment.

Biktarvy Dosing in Patients with Renal Impairment:
- Biktarvy is not recommended for use in patients with estimated creatinine clearance <30 mL/min.
### Dosing Recommendations

**Neonate and Infant Dose:**
- Dolutegravir (DTG) is not approved for use in neonates or infants.

**Child (Weighing <20 kg) Dose:**
- No dosing recommendations can be made for children weighing <20 kg.

**Child and Adolescent (Weighing ≥20 kg to <40 kg) Dose:**
- The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends using an investigational dose of DTG 50 mg once daily for children and adolescents weighing ≥20 kg who are antiretroviral therapy (ART)-naive or ART-experienced (but integrase strand transfer inhibitor [INSTI]-naive) and who are not being treated with uridine diphosphate glucuronyl transferase (UGT) 1A1 or cytochrome P450 (CYP) 3A inducers or inhibitors.
- DTG is not approved by the Food and Drug Administration (FDA) for use in children weighing <30 kg. However, interim data from ongoing trials indicate that using the FDA-approved dose of DTG 35 mg in patients weighing ≥30 kg to 40 kg may result in suboptimal trough concentrations, and additional data supports the 50-mg dose recommended by the Panel (see text). Using a 50-mg dose also avoids the need to administer two tablets with different strengths (i.e., a 10-mg tablet plus a 25-mg tablet).

### Selected Adverse Events

- Insomnia
- Headache
- Neuropsychiatric symptoms (i.e., depression and/or suicidal thoughts or actions), especially in patients with a history of psychiatric illness
- Rare cases of hypersensitivity reactions, including rash and drug reaction (or rash) with eosinophilia and systemic symptoms, constitutional symptoms, and organ dysfunction (including liver injury) have been reported.

### Special Instructions

- DTG may be taken without regard to meals.
- DTG should be taken 2 hours before or 6 hours after taking cation-containing antacids or laxatives, sucralfate, oral iron supplements, oral calcium supplements, or buffered medications.
- In patients who have difficulty swallowing tablets whole, 10-mg, 25-mg, and 50-mg tablets may be either split into halves followed by immediate ingestion of both halves of the tablet, or crushed and added to a small amount of semisolid food or liquid, all of which should be consumed immediately.\(^1\)
- The efficacy of DTG 50 mg twice daily is reduced in patients with certain combinations of INSTI-resistance mutations (see the Resistance section below).
Patients should be tested for hepatitis B virus (HBV) infection prior to use of Triumeq or Dovato. Lamivudine (3TC)-resistant HBV variants have been reported in patients who received 3TC-containing ARV regimens. Patients with HBV/HIV coinfection who receive Dovato will require additional treatment for chronic HBV infection. Severe exacerbation of hepatitis can occur in patients with HBV/HIV coinfection who discontinue 3TC.

**Metabolism/Elimination**

- UGT1A1 and CYP3A substrate. Drugs that induce these enzymes and transporters may decrease plasma concentrations of DTG. Drugs that inhibit these enzymes may increase DTG plasma concentrations.

**Dolutegravir Dosing in Patients with Hepatic Impairment:**

- No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Due to a lack of data, DTG is not recommended for use in patients with severe hepatic impairment.
- DTG decreases tubular secretion of creatinine and increases measured serum creatinine, without affecting glomerular filtration.

**Dolutegravir Dosing in Patients with Renal Impairment:**

- No dose adjustment is required in INSTI-naive patients with mild, moderate, or severe renal impairment, or in INSTI-experienced patients with mild or moderate renal impairment.
- Use DTG with caution in INSTI-experienced patients with severe renal impairment (creatinine clearance <30 mL/min), because DTG concentrations will be decreased. The cause of this decrease is unknown.

---

**[Dovato] Dolutegravir/Lamivudine**

**Adult Dose:**

- One tablet once daily with or without food as a complete regimen in ARV-naive adults with no known mutations associated with resistance to the individual components of Dovato.
- Dovato is not approved by the FDA or recommended by the Panel for use in children or adolescents as a complete regimen. However, it could be used as part of a three-drug regimen in patients who meet the minimum body weight requirements for each component drug (see the Simplification of Treatment section below).

**[Juluca] Dolutegravir/Rilpivirine**

**Adult Dose:**

- One tablet once daily with a meal as a complete regimen to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ARV regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Juluca.
- Juluca is not approved by the FDA or recommended by the Panel for use in children or adolescents as a complete regimen (see the Simplification of Treatment section below).

---

**[Triumeq] Abacavir/Dolutegravir/Lamivudine**

**Child and Adolescent (Weighing ≥25 kg) and Adult Dose:**

- One tablet once daily with or without food.
- For use in patients who are ARV-naive or ARV-experienced (but INSTI-naive) and who are not...
being treated with UGT1A1 or CYP3A inducers.

- See the Abacavir section for special instructions about testing for abacavir hypersensitivity.
- The FDA-approved dose for pediatric patients weighing \(\geq 40\) kg is one tablet once daily.
Elvitegravir (EVG)  *(Last updated April 14, 2020; last reviewed April 14, 2020)*

**Formulations**

**Tablet:** Discontinued by the manufacturer. Elvitegravir is only available in fixed-dose combination (FDC) tablets.

**Fixed-Dose Combination Tablets:**
- [Genvoya] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg
- [Stribild] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg

When using FDC tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents.

For additional information, see Drugs@FDA or DailyMed.

---

### Dosing Recommendations

**[Genvoya] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (TAF)**

**Child (Weighing <25 kg) Dose:**
- There are no data on the appropriate dose of Genvoya for children weighing <25 kg.

**Child and Adolescent (Weighing ≥25 kg) and Adult Dose:**
- One tablet once daily with food in antiretroviral therapy (ART)-naive patients. This dose of Genvoya can also be used to replace the current antiretroviral (ARV) regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a stable ART regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Genvoya.

**[Stribild] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)**

**Child and Adolescent (Weighing <35 kg) Dose:**
- There are no data on the appropriate dose of Stribild for children or adolescents weighing <35 kg.

**Adolescent (Weighing ≥35 kg and Sexual Maturity Rating [SMR] 4 or 5) and Adult Dose:**
- One tablet once daily with food in ART-naive patients. This dose of Stribild can also be used to replace the current ARV regimen in patients who have been virologically suppressed (HIV RNA <50 copies/mL) on a

### Selected Adverse Events

**Elvitegravir-Associated Adverse Events:**
- Diarrhea

**Stribild-Associated Adverse Events:**
- Nausea
- Diarrhea
- Fatigue
- Headache

**TDF-Specific Adverse Events:**
- Glomerular and proximal renal tubular dysfunction
- Decreased bone mineral density
- Flatulence

**Cobicistat-Specific Adverse Events:**
- Benign increases in serum creatinine levels (reductions in estimated glomerular filtration) due to inhibition of tubular secretion of creatinine

**Genvoya-Associated Adverse Events:**
- Nausea
- Diarrhea
- Fatigue
- Headache

**TAF-Specific Adverse Events:**
- Increased levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and total cholesterol

**Cobicistat-Specific Adverse Events:**
- Benign increases in serum creatinine levels
stable ART regimen for at least 6 months with no history of treatment failure and no known mutations associated with resistance to the individual components of Stribild.

(reductions in estimated glomerular filtration) due to inhibition of tubular secretion of creatinine

**Special Instructions**

- Administer both Genvoya and Stribild with food.
- EVG should be administered at least 4 hours before or after antacids and supplements or multivitamins that contain iron, calcium, aluminum, and/or magnesium.
- When using Stribild, which contains TDF, monitor estimated creatinine clearance (CrCl), urine glucose, and urine protein at baseline and every 3 to 6 months while on therapy. In patients who are at risk of renal impairment, also monitor serum phosphate. Patients with an increase in serum creatinine levels >0.4 mg/dL should be closely monitored for renal safety.
- Screen patients for hepatitis B virus (HBV) infection before using emtricitabine (FTC), TDF, or TAF. Severe acute exacerbation of HBV can occur when FTC, TDF, or TAF are discontinued; therefore, monitor hepatic function for several months after stopping therapy with FTC, TDF, or TAF.
- For information on crushing and cutting tablets, please see this table from Toronto General Hospital.

**Metabolism/Elimination**

- EVG is metabolized by cytochrome P450 (CYP) 3A4 and is a modest inducer of CYP2C9.
- EVG should only be used with the pharmacokinetic enhancer (boosting agent) cobicistat in Stribild or Genvoya. Refer to the TDF and TAF sections for further details.

**Elvitegravir Dosing in Patients with Hepatic Impairment:**

- Stribild and Genvoya **should not be used** in patients with severe hepatic impairment.

**Elvitegravir Dosing in Patients with Renal Impairment:**

- Stribild **should not be initiated** in patients with estimated CrCl <70 mL/min, and it should be discontinued in patients with estimated CrCl <50 mL/min. FTC and TDF require dose adjustments in these patients, and these adjustments cannot be achieved with an FDC tablet.
- Genvoya **should not be initiated** in patients with estimated CrCl <30 mL/min.
**Dosing Recommendations**

**Note:** No dosing information is available for preterm infants or infants weighing <2 kg at birth. See Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection and Table 12 for information about using raltegravir (RAL) for the prevention of perinatal HIV transmission.

**Neonate (Weighing ≥2 kg) Dose:**
- RAL is metabolized by uridine diphosphate glucuronyl transferase (UGT1A1), and enzyme activity is low at birth; enzyme activity increases rapidly during the next 4 to 6 weeks of life.

**Raletgravir Oral Suspension Dosing Table for Full-Term Neonates from Birth to Age 4 Weeks**

**Neonates Aged ≥37 Weeks and Weighing ≥2 kg:**

<table>
<thead>
<tr>
<th>Weight</th>
<th>Volume (Dose) of Suspension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth to 1 Week of Age: Once-Daily Dosing</td>
<td>Approximately 1.5 mg/kg per dose</td>
</tr>
<tr>
<td>2 kg to &lt;3 kg</td>
<td>0.4 mL (4 mg) once daily</td>
</tr>
<tr>
<td>3 kg to &lt;4 kg</td>
<td>0.5 mL (5 mg) once daily</td>
</tr>
<tr>
<td>4 kg to &lt;5 kg</td>
<td>0.7 mL (7 mg) once daily</td>
</tr>
<tr>
<td>1–4 Weeks of Age: Twice-Daily Dosing</td>
<td>Approximately 3 mg/kg per dose</td>
</tr>
<tr>
<td>2 kg to &lt;3 kg</td>
<td>0.8 mL (8 mg) twice daily</td>
</tr>
<tr>
<td>3 kg to &lt;4 kg</td>
<td>1 mL (10 mg) twice daily</td>
</tr>
<tr>
<td>4 kg to &lt;5 kg</td>
<td>1.5 mL (15 mg) twice daily</td>
</tr>
</tbody>
</table>

**Infant and Child (Weighing ≥3 kg to <20 kg) Dose:**
- For children weighing 11 kg to 20 kg, either oral suspension or chewable tablets can be used.

**Special Instructions**

- RAL can be given without regard to food.
- Coadministration or staggered administration of aluminum-containing and magnesium-containing antacids is not recommended with any RAL formulations.
- Significant drug interactions are more likely to occur when the RAL HD formulation is used once daily. The following drugs should not be coadministered with once daily RAL HD dosing: calcium carbonate, rifampin, tipranavir/ritonavir, and etravirine.
- Chewable tablets can be chewed, crushed (before administration), or swallowed whole.
- Film-coated tablets, including HD tablets, must be swallowed whole.
- The chewable tablets and oral suspension have better bioavailability than the film-coated tablets. Because the formulations are not interchangeable, do not substitute chewable tablets or oral suspension for film-coated tablets. See specific recommendations for proper dosing of different formulations.

**Selected Adverse Events**

- Rash, including Stevens-Johnson syndrome, hypersensitivity reaction, and toxic epidermal necrolysis
- Nausea, diarrhea
- Headache, dizziness, fatigue
- Insomnia
- Fever
- Creatine phosphokinase elevation, muscle weakness, and rhabdomyolysis

**Forms:**
- Tablet: 400 mg (film-coated poloxamer tablet)
- High-Dose (HD) Tablet: 600 mg (film-coated poloxamer tablet)
- Chewable Tablets: 100 mg (scored) and 25 mg
- Granules for Oral Suspension: Single-use packet of 100 mg of raltegravir, suspended in 10 mL of water for a final concentration of 10 mg/mL.

Film-coated tablets, chewable tablets, and oral suspension are not interchangeable.

For additional information, see Drugs@FDA or DailyMed.
**Raltegravir Oral Suspension Dosing Table for Patients Aged >4 Weeks**

**Note:** The maximum dose of oral suspension is 10 mL (RAL 100 mg) twice daily.

<table>
<thead>
<tr>
<th>Weight</th>
<th>Twice-Daily Volume (Dose) of Suspension</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 kg to &lt;4 kg</td>
<td>2.5 mL (25 mg)</td>
</tr>
<tr>
<td>4 kg to &lt;6 kg</td>
<td>3 mL (30 mg)</td>
</tr>
<tr>
<td>6 kg to &lt;8 kg</td>
<td>4 mL (40 mg)</td>
</tr>
<tr>
<td>8 kg to &lt;11 kg</td>
<td>6 mL (60 mg)</td>
</tr>
<tr>
<td>11 kg to &lt;14 kg</td>
<td>8 mL (80 mg)</td>
</tr>
<tr>
<td>14 kg to &lt;20 kg</td>
<td>10 mL (100 mg)</td>
</tr>
</tbody>
</table>

*The weight-based dose recommendation for the oral suspension is based on a dose of approximately RAL 6 mg/kg per dose twice daily.*

---

**Child and Adolescent Dose for Chewable Tablets, Film-Coated Tablets, and High-Dose Tablets**

**Children Weighing ≥11 kg**

**Weighing <25 kg:**
- Chewable tablets twice daily. See the table below for chewable tablet doses.

**Weighing ≥25 kg:**
- RAL 400-mg, film-coated tablets twice daily or chewable tablets twice daily. See the table below for chewable tablet doses.

**Children and Adolescents Weighing ≥40 kg:**
- Two RAL 600-mg HD tablets (1,200 mg) once daily
- This dose is for antiretroviral therapy-naive or virologically suppressed patients who are on an initial dose of RAL 400 mg twice daily.

**Chewable Tablet Dosing Table**

**Note:** The maximum dose of chewable tablets is RAL 300 mg twice daily.

<table>
<thead>
<tr>
<th>Weight</th>
<th>Twice-Daily Dose</th>
<th>Number of Chewable Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 kg to &lt;14 kg</td>
<td>RAL 75 mg</td>
<td>3 tablets (25 mg) twice daily</td>
</tr>
<tr>
<td>14 kg to &lt;20 kg</td>
<td>RAL 100 mg</td>
<td>1 tablet (100 mg) twice daily</td>
</tr>
<tr>
<td>20 kg to &lt;28 kg</td>
<td>RAL 150 mg</td>
<td>1 ½ tablets (100 mg) twice daily</td>
</tr>
<tr>
<td>28 kg to &lt;40 kg</td>
<td>RAL 200 mg</td>
<td>2 tablets (100 mg) twice daily</td>
</tr>
<tr>
<td>≥40 kg</td>
<td>RAL 300 mg</td>
<td>3 tablets (100 mg) twice daily</td>
</tr>
</tbody>
</table>

*The weight-based dose recommendation for the chewable tablet is based on a dose of approximately RAL 6 mg/kg per dose twice daily.*

---

- The chewable tablets should be stored in the original package with a desiccant to protect them from moisture.
- The chewable tablets contain phenylalanine, a component of aspartame. Phenylalanine can be harmful to patients with phenylketonuria, and the necessary dietary adjustments should be made in consultation with a metabolic specialist.
- The oral suspension comes in a kit that includes mixing cups, oral dosing syringes, and 60 foil packets. Detailed instructions for preparation are provided in the Instructions for Use document. Each single-use foil packet contains 100 mg of RAL, which will be suspended in 10 mL of water for a final concentration of RAL 10 mg/mL. Gently swirl the mixing cup for 45 seconds in a circular motion to mix the powder into a uniform suspension.

- **Do not shake the oral suspension.** Dose should be administered within 30 minutes of mixing; unused solution should be discarded as directed in the Instructions for Use document. For neonates, most of the prepared oral suspension will be discarded, as the volume for the required dose is much smaller than 10 mL.

---

**Metabolism/Elimination**

- UGT1A1-mediated glucuronidation

**Raltegravir Dosing in Patients with Hepatic Impairment:**
- No dose adjustment is necessary for patients with mild-to-moderate hepatic insufficiency who are receiving RAL twice daily.
- No dose adjustment is necessary for patients with mild-to-moderate hepatic insufficiency who are receiving either RAL 1,200 mg once daily or RAL 400 mg twice daily.
- No studies have been conducted on the use of RAL HD in patients with hepatic impairment. Therefore, administering RAL HD is not recommended in patients with hepatic impairment.
- The effect of severe hepatic impairment on RAL pharmacokinetics has not been studied.

**Raltegravir Dosing in Patients with Renal Impairment:**
- No dose adjustment is necessary in patients with any degree of renal impairment.
The RAL 100-mg chewable tablet can be divided into equal halves.
Pharmacokinetic Enhancers

Cobicistat (COBI, TYBOST)
Ritonavir (RTV, Norvir)
**Cobicistat (COBI, Tybost)**

**(Last updated April 14, 2020; last reviewed April 14, 2020)**

**Formulations**

**Tablet:** 150 mg

**Fixed-Dose Combination Tablets:**

- [Evotaz] Atazanavir 300 mg/cobicistat 150 mg
- [Genvoya] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg
- [Prezobrix] Darunavir 800 mg/cobicistat 150 mg
- [Stribild] Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg
- [Symtuza] Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg

When using fixed-dose combination (FDC) tablets, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents. For additional information, see Drugs@FDA or DailyMed.

**Dosing Recommendations**

**Cobicistat is a Pharmacokinetic Enhancer:**
- The only use of cobicistat (COBI) is as a pharmacokinetic (PK) enhancer (boosting agent) for certain protease inhibitors (PIs) and integrase strand transfer inhibitors. COBI is not interchangeable with ritonavir (RTV).

**Child and Adolescent (Weighing ≥35 kg) and Adult Dose:**
- COBI 150 mg with atazanavir (ATV) 300 mg administered at the same time and with food

**Child and Adolescent (Weighing ≥40 kg) and Adult Dose:**
- COBI 150 mg with darunavir (DRV) 800 mg administered at the same time and with food

**[Evotaz] Atazanavir/Cobicistat**

**Child and Adolescent (Weighing ≥35 kg) and Adult Dose:**
- One tablet once daily with food
- Use in combination with other ARV drugs.

**[Genvoya] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (TAF)**

**Child and Adolescent (Weighing ≥25 kg) and Adult Dose:**
- One tablet once daily with food

**[Prezobrix] Darunavir/Cobicistat**

**Child and Adolescent (Weighing ≥40 kg) and Adult Dose:**
- One tablet once daily with food

**Selected Adverse Events**

- COBI is an inhibitor of renal tubular transporters of creatinine. This increases serum creatinine and reduces estimated glomerular filtration rate, with no change in glomerular function.

**Special Instructions**

- COBI 150 mg is not interchangeable with RTV, but it has a PK boosting effect that is comparable to RTV 100 mg.
- Drug interactions may differ between RTV and COBI, because COBI is a stronger P-glycoprotein inhibitor and lacks some of the induction effects of RTV.
- Do not administer COBI with RTV or with FDC tablets that contain COBI.
- COBI is not recommended for use with more than one ARV drug that requires PK enhancement (e.g., elvitegravir used in combination with a PI).
- Using COBI with PIs other than once-daily ATV 300 mg or DRV 800 mg is not recommended.
- Patients with a confirmed increase in serum creatinine >0.4 mg/dL from baseline should be closely monitored for renal safety.
- When using COBI in combination with TDF, monitor serum creatinine, urine protein, and urine glucose at baseline and every 3 to 6 months while the patient is receiving therapy (see Table 15i). In patients who are at risk of
- Use in combination with other ARV drugs.

**[Stribild]** Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
Child and Adolescent (Weighing ≥35 kg) and Adult Dose:
  - One tablet once daily with food
  - The Panel recommends using Stribild only in patients with sexual maturity ratings of 4 or 5.

**[Symtuza]** Darunavir/Cobicistat/Emtricitabine/TAF
Child and Adolescent (Weighing ≥40 kg) and Adult Dose:
  - One tablet once daily with food

renal impairment, serum phosphate should also be monitored.

- For information on crushing and cutting tablets, please see this table from Toronto General Hospital.

**Metabolism/Elimination**
- COBI is a strong inhibitor of cytochrome P450 (CYP) 3A4 and a weak inhibitor of CYP2D6.

**Cobicistat Dosing in Patients with Hepatic Impairment:**
- COBI does not require dose adjustment in patients with mild to moderate hepatic impairment. No data are available in patients with severe hepatic impairment. Dosing recommendations for medications that are coadministered with COBI should be followed.¹
- Stribild, Genvoya, and Symtuza should not be used in patients with severe hepatic impairment.¹

**Cobicistat Dosing in Patients with Renal Impairment:**
- COBI does not require a dose adjustment in patients with renal impairment, including those with severe renal impairment. Dosing recommendations for medications that are coadministered with COBI should be followed.¹
- The use of COBI plus TDF is not recommended in patients with creatinine clearance (CrCl) <70 mL/min. Dose adjustments for TDF are required for patients with CrCl <50 mL/min, and the necessary dose adjustments for TDF when this drug is used with COBI have not been established in this group of patients.¹
- Stribild should not be initiated in patients with estimated CrCl <70 mL/min and should be discontinued in patients with estimated CrCl <50 mL/min. The dose adjustments required for emtricitabine and TDF in these patients cannot be achieved with an FDC tablet.
- Neither Genvoya nor Symtuza should be initiated in patients with estimated CrCl <30 mL/min.
### Ritonavir (RTV, Norvir)  *(Last updated April 14, 2020; last reviewed April 14, 2020)*

#### Formulations

**Oral Powder:** 100 mg per packet  
**Oral Solution:** 80 mg/mL. Oral solution contains 43% (v/v) ethanol and approximately 27% (w/v) propylene glycol.  
**Tablets:** 100 mg  
**Generic Formulation**  
- 100 mg tablets  
**Fixed-Dose Combination Solution:**  
- [Kaletra] Lopinavir 80 mg/ritonavir 20 mg/mL. Oral solution contains 42.4% (v/v) ethanol and 15.3% (w/v) propylene glycol.  
**Fixed-Dose Combination Tablets:**  
- [Kaletra] Lopinavir 100 mg/ritonavir 25 mg  
- [Kaletra] Lopinavir 200 mg/ritonavir 50 mg  

When using fixed-dose combination (FDC) tablets or solution, refer to other sections of the Drug Appendix for information about the individual components of the FDC. See also Appendix A, Table 2, Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents. For additional information, see Drugs@FDA or DailyMed.

#### Dosing Recommendations

**Ritonavir as a Pharmacokinetic Enhancer:**  
- Ritonavir (RTV) is used as a pharmacokinetic enhancer of other protease inhibitors (PIs). The recommended dose of RTV varies and is specific to the drug combination selected. See other sections of the Drug Appendix for information about the recommended doses of RTV to use with specific PIs. RTV has antiviral activity, but it is not used as an antiviral agent; instead, it is used as a pharmacokinetic enhancer of other PIs.

**Formulation Considerations:**  
- The RTV oral solution contains propylene glycol and ethanol.  
- The oral powder is preferred over the oral solution for children who cannot swallow the tablets and who need a dose of at least RTV 100 mg, because the oral powder does not contain propylene glycol or ethanol.  
- RTV oral powder should be used only for dosing increments of 100 mg and cannot be used for doses <100 mg.

#### Selected Adverse Events

- Gastrointestinal (GI) intolerance, nausea, vomiting, diarrhea  
- Hyperlipidemia, especially hypertriglyceridemia  
- Hepatitis  
- Hyperglycemia  
- Fat maldistribution

#### Special Instructions

- Administer RTV with food to increase absorption and reduce the likelihood and severity of GI adverse events.  
- **Do not administer** RTV with cobicistat (COBI) or drugs that contain COBI (e.g., Stribild, Genvoya, Prezobix, Evotaz).  
- **Do not refrigerate** RTV oral solution; store at 68°F to 77°F (20°C to 25°C). Shake the solution well before use.  
- RTV oral powder should be mixed with a soft food (e.g., apple sauce, vanilla pudding) or a liquid (e.g., water, chocolate milk, infant formula) to help mitigate the bitter taste.
**[Kaletra] Lopinavir/Ritonavir**

**Infant, Child, Adolescent, and Adult Dose:**

- See the [Lopinavir/Ritonavir](https://aidsinfo.nih.gov/guidelines) section of the Drug Appendix.

Administer or discard the mixture within 2 hours of mixing.

**To Increase Tolerability of Ritonavir Oral Solution or Oral Powder in Children:**

- Mix the solution or powder with milk, chocolate milk, ice cream, or vanilla or chocolate pudding.
- Before administering RTV, give a child ice chips, a Popsicle, or spoonfuls of partially frozen orange or grape juice concentrate to dull the taste buds. Another option is to give a nonallergic child peanut butter or hazelnut chocolate spread to coat the mouth.1
- After administration, give foods with strong tastes (e.g., maple syrup, cheese).
- Check a child’s food allergy history before making these recommendations.
- Counsel caregivers or patients that the bad taste will not be completely masked.

**Metabolism/Elimination**

- Cytochrome P450 (CYP) 3A and CYP2D6 inhibitor; CYP1A2, CYP2B6, CYP2C9, CYP2C19, and glucuronidation inducer. RTV inhibits the intestinal transporter P-glycoprotein.

**Ritonavir Dosing in Patients with Hepatic Impairment:**

- RTV is primarily metabolized by the liver.
- No dose adjustment is necessary in patients with mild or moderate hepatic impairment.
- There are no data on RTV dosing for adult or pediatric patients with severe hepatic impairment. Use caution when administering RTV to patients with moderate-to-severe hepatic impairment.
Overview

The Archived Drugs section of Appendix A: Pediatric Antiretroviral Drug Information provides access to the last updated versions of drug sections that are no longer being reviewed by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel). Archived Drugs includes older antiretroviral drugs that the Panel does not recommend for use in children because they have unacceptable toxicities, inferior virologic efficacy, a high pill burden, pharmacologic concerns, and/or a limited amount of pediatric data.

Didanosine
Enfuvirtide
Fosamprenavir
Indinavir
Nelfinavir
Saquinavir
Stavudine
Tipranavir
Didanosine (ddl, Videx) (Last updated May 22, 2018; last reviewed May 22, 2018)

For additional information, see Drugs@FDA: http://www.accessdata.fda.gov/scripts/cder/daf/

Formulations

Pediatric Oral Solution: 10 mg/mL

Enteric-Coated (EC) Delayed-Release Capsules (EC Beadlets): 125 mg, 200 mg, 250 mg, and 400 mg

Generic Formulations

Delayed-Release Capsules: 125 mg, 200 mg, 250 mg, and 400 mg

Dosing Recommendations

Note: Didanosine is no longer recommended by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV for use in children due to higher rates of adverse effects than other NRTIs.

Neonate/Infant Dose (Aged 2 Weeks to <3 Months):
- 50 mg/m² of body surface area every 12 hours. See dosing section below for justification of this dose.

Infant Dose (Aged ≥3 Months to 8 Months):
- 100 mg/m² body surface area every 12 hours

Pediatric Dose of Oral Solution (Age >8 Months):
- 120 mg/m² body surface area every 12 hours
- Dose range: 90–150 mg/m² body surface area every 12 hours. Do not exceed maximum adult dose; see table below.
- In treatment-naive children ages 3 years to 21 years, 240 mg/m² body surface area once daily (oral solution or capsules) has resulted in viral suppression.

Pediatric Dose of Videx EC or Generic Capsules (Aged 6–18 Years and Weighing ≥20 kg)

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 kg to &lt;25 kg</td>
<td>200 mg once daily</td>
</tr>
<tr>
<td>25 kg to &lt;60 kg</td>
<td>250 mg once daily</td>
</tr>
<tr>
<td>≥60 kg</td>
<td>400 mg once daily</td>
</tr>
</tbody>
</table>

Adolescent and Adult Dose

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;60 kg</td>
<td>250 mg once daily</td>
</tr>
<tr>
<td>≥60 kg</td>
<td>400 mg once daily</td>
</tr>
</tbody>
</table>

Selected Adverse Events

- Peripheral neuropathy
- Diarrhea, abdominal pain, nausea, and vomiting
- Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported (the risk is increased when didanosine is used in combination with stavudine).
- Pancreatitis (less common in children than in adults, more common when didanosine is used in combination with tenofovir disoproxil fumarate or stavudine)
- Non-cirrhotic portal hypertension
- Retinal changes, optic neuritis
- Insulin resistance/diabetes mellitus

Special Instructions

- Administer didanosine on an empty stomach (30 minutes before or 2 hours after a meal). To improve adherence, some practitioners administer didanosine without regard to timing of meals (see text below).
- Didanosine powder for oral solution contains antacids that may interfere with the absorption of other medications, including protease inhibitors (PIs). See individual PI for instructions on timing of administration.
- Shake didanosine oral solution well before use. Keep refrigerated; solution is stable for 30 days.

Metabolism/Elimination

- Renal excretion 50%
**Pediatric and Adolescent Dose of Didanosine when Combined with Tenofovir Disoproxil Fumarate:**

- This combination should be avoided because of enhanced didanosine toxicity, reports of immunologic nonresponse, high rates of early virologic failure, and rapid selection of resistance mutations (see the Adult and Adolescent Guidelines).

- Decrease dosage in patients with impaired renal function. Consult manufacturer’s prescribing information for adjustment of dosage in accordance with creatinine clearance.
Enfuvirtide (T-20, Fuzeon)  *(Last updated May 22, 2018; last reviewed May 22, 2018)*

For additional information, see Drugs@FDA: [http://www.accessdata.fda.gov/scripts/cder/daf/](http://www.accessdata.fda.gov/scripts/cder/daf/)

### Formulations

**Lyophilized Powder for Injection:**
- 108-mg vial of enfuvirtide. Reconstitution with 1.1 mL sterile water will deliver 90 mg/mL.

**Convenience Kit:**
- 60 single-use vials of enfuvirtide (108-mg vial reconstituted as 90 mg/mL), 60 vials of sterile water for injection, 60 reconstitution syringes (3 mL), 60 administration syringes (1 mL), alcohol wipes.

### Dosing Recommendations

#### Pediatric and Adolescent Dose (Aged 6–16 Years)

**Children Aged <6 Years:**
- Not approved for use in children aged <6 years

**Children Aged ≥6 Years:**
- 2 mg/kg (maximum dose 90 mg [1 mL]) twice daily injected subcutaneously (SQ) into the upper arm, anterior thigh, or abdomen

#### Adolescent (Aged >16 Years) and Adult Dose:
- 90 mg (1 mL) twice daily injected SQ into the upper arm, anterior thigh, or abdomen

### Selected Adverse Events

- Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in up to 98% of patients.
- Increased rate of bacterial pneumonia (unclear association).
- Hypersensitivity reaction (HSR)—symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Rechallenge is not recommended.

### Special Instructions

- Carefully instruct patient or caregiver in proper technique for drug reconstitution and administration of SQ injections. Enfuvirtide injection instructions are provided with convenience kits.
- Allow reconstituted vial to stand until the powder goes completely into solution, which could take up to 45 minutes. Do not shake.
- Once reconstituted, inject enfuvirtide immediately or keep refrigerated in the original vial until use. Reconstituted enfuvirtide must be used within 24 hours.
- Enfuvirtide must be given SQ; severity of reactions increases if given intramuscularly.
- Give each injection at a site different from the preceding injection site; do not inject into moles, scar tissue, bruises, or the navel. Both the patient/caregiver and health care provider should carefully monitor for signs and symptoms of local infection or cellulitis.
- To minimize local reactions, apply ice or heat after injection or gently massage injection site.
site to better disperse the dose. There are reports of injection-associated neuralgia and paresthesia when alternative delivery systems, such as needle-free injection devices, are used.

- Advise patients/caregivers of the possibility of a HSR; instruct them to discontinue treatment and seek immediate medical attention if a patient develops signs and symptoms consistent with a HSR.

**Metabolism/Elimination**

- Catabolism to constituent amino acids.
Dosing Recommendations

Pediatric Dose (Aged >6 Months to 18 Years):

- Unboosted fosamprenavir (without ritonavir) is Food and Drug Administration (FDA)-approved for antiretroviral (ARV)-naive children aged 2 to 5 years, but not recommended by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) because of low exposures (see text below).
- Boosted fosamprenavir (with ritonavir) is FDA-approved for ARV-naive infants ≥4 weeks and for treatment-experienced infants ≥6 months; however, the Panel does not recommend use in infants aged <6 months because of similarly low exposures (see text below). If used in infants as young as 4 weeks, it should only be administered to infants born at 38 weeks’ gestation or greater.

Note: Once-daily dosing is not recommended for any pediatric patient.

Pediatric Dose (Aged ≥6 Months to 18 Years):

Twice-Daily Dose Regimens by Weight for Pediatric Patients ≥6 Months Using Fosamprenavir Oral Suspension with Ritonavir

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dose (Both Drugs Twice Daily* with Food)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;11 kg</td>
<td>Fosamprenavir 45 mg/kg/dose plus ritonavir 7 mg/kg/dose</td>
</tr>
<tr>
<td>11 kg to</td>
<td>Fosamprenavir 30 mg/kg/dose plus ritonavir 3 mg/kg/dose</td>
</tr>
<tr>
<td>&lt;15 kg</td>
<td></td>
</tr>
<tr>
<td>15 kg to</td>
<td>Fosamprenavir 23 mg/kg/dose plus ritonavir 3 mg/kg/dose</td>
</tr>
<tr>
<td>&lt;20 kg</td>
<td></td>
</tr>
<tr>
<td>≥20 kg</td>
<td>Fosamprenavir 18 mg/kg/dose plus ritonavir 3 mg/kg/dose</td>
</tr>
</tbody>
</table>

* Not to exceed the adult dose of fosamprenavir 700 mg plus ritonavir 100 mg twice daily.

Selected Adverse Events

- Diarrhea, nausea, vomiting
- Skin rash (fosamprenavir has a sulfonamide moiety. Stevens-Johnson syndrome and erythema multiforme have been reported.)
- Headache
- Hyperlipidemia, hyperglycemia
- Nephrolithiasis
- Transaminase elevation
- Fat maldistribution
- Possible increased bleeding episodes in patients with hemophilia

Special Instructions

- Fosamprenavir tablets with ritonavir should be taken with food. Children should take the suspension with food.
- Patients taking antacids should take fosamprenavir at least 1 hour before or after antacid use.
- Fosamprenavir contains a sulfonamide moiety. The potential for cross sensitivity between fosamprenavir and other drugs in the sulfonamide class is unknown. Fosamprenavir should be used with caution in patients with sulfonamide allergy.
- Shake oral suspension well before use. Refrigeration is not required.

Metabolism/Elimination

- The prodrug fosamprenavir is rapidly and almost completely hydrolyzed to amprenavir by cellular phosphatases in the gut as it is absorbed.
- Amprenavir is a cytochrome P (CYP) 450 3A4 inhibitor, inducer, and substrate.
Fosamprenavir Dosing in Patients with Hepatic Impairment:
• Specific dose adjustments are recommended for adults with mild, moderate, and severe hepatic impairment. However, there are no data to support dosing recommendations for pediatric patients with hepatic impairment. Please refer to the package insert.

Fosamprenavir Dosing in Patients with Renal Impairment:
• No dose adjustment is required in patients with renal impairment.

**Note:** When administered with ritonavir, the adult regimen of 700 mg fosamprenavir tablets plus 100 mg ritonavir, both given twice daily, can be used in patients weighing ≥39 kg. Ritonavir tablets can be used in patients weighing ≥33 kg.

**Adolescent and Adult Dose:**
• Dosing regimen depends on whether the patient is ARV-naive or ARV-experienced.

**ARV-Naive Patients**
• Fosamprenavir 700 mg plus ritonavir 100 mg, both twice daily
• Fosamprenavir 1400 mg plus ritonavir 100–200 mg, both once daily

**Protease-Inhibitor-Experienced Patients:**
• Fosamprenavir 700 mg plus ritonavir 100 mg, both twice daily

**Note:** Once-daily administration of fosamprenavir plus ritonavir is not recommended.
Selected Adverse Events
- Nephrolithiasis
- Gastrointestinal intolerance, nausea
- Hepatitis
- Indirect hyperbilirubinemia
- Hyperlipidemia
- Hyperglycemia
- Fat maldistribution
- Possible increased bleeding episodes in patients with hemophilia

Special Instructions
- When indinavir is given in combination with ritonavir, meal restrictions are not necessary.
- Adequate hydration is required to minimize risk of nephrolithiasis (≥48 oz of fluid daily in adult patients).
- Indinavir capsules are sensitive to moisture; store at room temperature (59–86°F) in original container with desiccant.

Metabolism/Elimination
- Cytochrome P450 3A4 (CYP3A4) inhibitor and substrate

Indinavir Dosing in Patients with Hepatic Impairment:
- Dose should be decreased in patients with mild-to-moderate hepatic impairment (recommended dose for adults is 600 mg indinavir every 8 hours). No dosing information is available for children with any degree of hepatic impairment or for adults with severe hepatic impairment.
**Nelfinavir (NFV, Viracept)** (Last updated May 22, 2018; last reviewed May 22, 2018)

For additional information, see Drugs@FDA: [http://www.accessdata.fda.gov/scripts/cder/daf/](http://www.accessdata.fda.gov/scripts/cder/daf/)

### Formulations

**Tablets:** 250 mg and 625 mg

<table>
<thead>
<tr>
<th>Dosing Recommendations</th>
<th>Selected Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Note:</strong> The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV <strong>no longer recommends</strong> nelfinavir-based regimens for use in children due to inferior potency compared to other regimens.</td>
<td>• Diarrhea</td>
</tr>
<tr>
<td><strong>Neonate and Infant Dose:</strong></td>
<td>• Hyperlipidemia</td>
</tr>
<tr>
<td>• Nelfinavir should not be used for treatment in children aged &lt;2 years.</td>
<td>• Hyperglycemia</td>
</tr>
<tr>
<td><strong>Pediatric Dose (Aged ≥2 Years):</strong></td>
<td>• Fat maldistribution</td>
</tr>
<tr>
<td>• 45–55 mg/kg twice daily</td>
<td>• Serum transaminase elevations</td>
</tr>
<tr>
<td><strong>Adolescent and Adult Dose:</strong></td>
<td><strong>Special Instructions</strong></td>
</tr>
<tr>
<td>• 1250 mg (five 250-mg tablets or two 625-mg tablets) twice daily</td>
<td>• Administer nelfinavir with meal or light snack.</td>
</tr>
<tr>
<td></td>
<td>• If co-administered with didanosine, administer nelfinavir 2 hours before or 1 hour after didanosine.</td>
</tr>
<tr>
<td></td>
<td>• Patients unable to swallow nelfinavir tablets can dissolve the tablets in a small amount of water. Once tablets are dissolved, mix the cloudy mixture well and consume it immediately. The glass should be rinsed with water and the rinse swallowed to ensure that the entire dose is consumed. Tablets can also be crushed and administered with pudding or other nonacidic foods.</td>
</tr>
</tbody>
</table>

**Metabolism/Elimination**

- Cytochrome P (CYP) 2C19 and 3A4 substrate
- Metabolized to active M8 metabolite
- CYP3A4 inhibitor
**Saquinavir (SQV, Invirase)** (Last updated May 22, 2018; last reviewed May 22, 2018)

For additional information, see Drugs@FDA: [http://www.accessdata.fda.gov/scripts/cder/daf](http://www.accessdata.fda.gov/scripts/cder/daf)

### Formulations
- **Capsules**: 200 mg
- **Tablets**: 500 mg

### Dosing Recommendations

**Pediatric Dose:**
- Not approved for use in infants, children, and adolescents aged <16 years.

**Adolescent and Adult Dose:**
- Saquinavir should **only** be used in combination with ritonavir.
- Saquinavir 1000 mg plus ritonavir 100 mg twice daily

### Selected Adverse Events
- Gastrointestinal intolerance, nausea, and diarrhea
- Elevated transaminases
- Hyperlipidemia
- Hyperglycemia
- Fat maldistribution
- PR interval prolongation, QT interval prolongation, and ventricular tachycardia (Torsades de Pointes)

### Special Instructions
- Administer within 2 hours after a full meal.
- Sun exposure can cause photosensitivity reactions; advise patients to use sunscreen or protective clothing.
- Pre-therapy electrocardiogram is recommended; saquinavir is **contraindicated** in patients with a prolonged QT interval.

### Metabolism/Elimination
- Cytochrome P450 3A4 (CYP3A4) substrate and inhibitor
- 90% metabolized in the liver
- Use saquinavir with caution in patients who have hepatic impairment; no dose adjustment recommended.
Stavudine (d4T, Zerit)  (Last updated May 22, 2018; last reviewed May 22, 2018)

For additional information, see Drugs@FDA: [http://www.accessdata.fda.gov/scripts/cder/daf/](http://www.accessdata.fda.gov/scripts/cder/daf/)

**Formulations**

**Powder for Oral Solution:** 1 mg/mL  
**Capsules:** 15 mg, 20 mg, 30 mg, and 40 mg

**Generic Formulations**

**Powder for Oral Solution:** 1 mg/mL  
**Capsules:** 15 mg, 20 mg, 30 mg, and 40 mg

**Dosing Recommendations**

**Note:** Stavudine **is no longer recommended** for use in children by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, because it causes higher rates of adverse effects than other nucleoside reverse transcriptase inhibitors (NRTIs).

**Pediatric (Aged ≥14 Days and Weighing <30 kg) Dose:**  
• 1 mg/kg per dose twice daily

**Adolescent (Weighing ≥30 kg) and Adult Dose:**  
• 30 mg per dose twice daily

**Selected Adverse Events**

• Associated with a higher risk of mitochondrial toxicity than other NRTI drugs  
• Peripheral neuropathy is dose-related and occurs more frequently in patients who have advanced HIV disease or a prior history of peripheral neuropathy, and in patients receiving other drugs associated with neuropathy.  
• Facial/peripheral lipoatrophy  
• Pancreatitis  
• Lactic acidosis/severe hepatomegaly with hepatic steatosis (higher incidence than with other NRTIs). The risk increases when stavudine is used in combination with didanosine.  
• Dyslipidemia  
• Insulin resistance, asymptomatic hyperglycemia  
• Rapidly progressive ascending neuromuscular weakness (rare)

**Special Instructions**

• Stavudine can be given without regard to food.  
• Shake stavudine oral solution well before use. Keep refrigerated; the solution is stable for 30 days.

**Metabolism/Elimination**

• Renal excretion 50%. Decrease dose in renal dysfunction.  
• Stavudine is phosphorylated intracellularly to the active metabolite stavudine triphosphate.
Tipranavir (TPV, Aptivus)  (Last updated May 22, 2018; last reviewed May 22, 2018)

For additional information, see Drugs@FDA: http://www.accessdata.fda.gov/scripts/cder/daf/

Formulations

Oral Solution: 100 mg tipranavir/mL, with 116 International Units (IU) vitamin E/mL
Capsules: 250 mg

Dosing Recommendations

**Note:** Tipranavir must be boosted with ritonavir. The ritonavir boosting dose used for tipranavir is higher than the doses used for other protease inhibitors.

**Pediatric (Aged <2 Years) Dose:**
- Not approved for use in children aged <2 years

**Pediatric (Aged 2–18 Years) Dose:**
**Note:** Not recommended for treatment-naive patients

**Body Surface Area Dosing:**
- Tipranavir/ritonavir (TPV/r) 375 mg/m²/150 mg/m², both twice daily (maximum dose is TPV/r 500 mg/200 mg, both twice daily)

**Weight-Based Dosing:**
- TPV/r 14 mg/kg/6 mg/kg, both twice daily (maximum dose is TPV/r 500 mg/200 mg, both twice daily)

**Adult Dose:**
- TPV/r 500 mg (as two 250-mg capsules)/200 mg, both twice daily
- **Note:** Not recommended for treatment-naive patients

Selected Adverse Events

- Rare cases of fatal and non-fatal intracranial hemorrhage
- Skin rash (more common in children than adults)
- Nausea, vomiting, diarrhea
- Hepatotoxicity: elevated transaminases; clinical hepatitis
- Hyperlipidemia
- Hyperglycemia
- Elevated creatine phosphokinase

Special Instructions

- Administer tipranavir and ritonavir together and with food.
- Tipranavir oral solution contains 116 IU vitamin E per mL, which is significantly higher than the reference daily intake for vitamin E. Patients taking the oral solution should avoid taking any form of supplemental vitamin E that contains more vitamin E than found in a standard multivitamin.
- Tipranavir contains a sulfonamide moiety and should be used with caution in patients with sulfonamide allergy.
- Store tipranavir oral solution at room temperature, 25°C (77°F); do not refrigerate or freeze. Oral solution must be used within 60 days after the bottle is first opened.
- Store unopened bottles of oral tipranavir capsules in a refrigerator at 2°C to 8°C (36°F to 46°F). Once the bottle has been opened, capsules can be kept at room temperature (maximum of 77°F or 25°C) if used within 60 days.
- Use tipranavir with caution in patients who may be at increased risk of intracranial hemorrhage, including individuals with brain
lesion, head trauma, recent neurosurgery, coagulopathy, hypertension, or alcoholism, or who use anticoagulant or antiplatelet agents (including vitamin E).

- Use of tipranavir is contraindicated in patients with moderate or severe hepatic impairment.

**Metabolism/Elimination**

- Cytochrome P450 3A4 (CYP3A4) inducer and substrate
- P-glycoprotein substrate

**Tipranavir Dosing in Patients with Renal Impairment:**

- No dose adjustment is required.

**Tipranavir Dosing in Patients with Hepatic Impairment:**

- No dose adjustment is required for mild hepatic impairment.
- Use of tipranavir is **contraindicated** in patients with moderate-to-severe hepatic impairment.